Home » Biology (Page 5)
Category Archives: Biology
The Relationship Between Itch and Pain in Itch Pathways
By Nathifa Nasim, Neurobiology, Physiology & Behavior ‘22
Author’s Note: Itch is not a stranger to any of us, but growing up with eczema, I have always been hyper aware of it. As far back as I can remember, burning hot showers and painful levels of scratching temporarily alleviated the maddening sensation of itch without my understanding of how pain was linked to itch. Once I joined the Carstens Lab studying the relationship between itch and pain, these memories were rekindled, and I became interested in not only understanding itch, which we know so little of, but how these two sensations interact. This paper was also written for my UWP 104E class.
Introduction
Itch is an everyday sensation that nearly all people have experienced. Its origins lie in its role as a defense mechanism — when faced with irritant stimuli, the scratching urge produced by itch can remove potentially harmful substances [1]. However, despite its evolutionary advantages, itch is often a source of discomfort and for many can dramatically impact their quality of life. Itch not only includes acute itch such as mosquito bites, but debilitating chronic itch can stem from different diseases such as cancer, HIV/AIDS, liver/kidney failure, atopic dermatitis, and other skin disorders [2]. However, despite the widespread impacts of itch, much of its mechanisms and pathways still remain elusive.
Itch is a somatosensory sensation, relying on the nervous system for detection and perception, therefore similar to other somatosensory sensations such as heat, touch, vibration, and most importantly, pain. Pain and itch have an antagonistic relationship, meaning each sensation has an opposing effect on the other. This is evident in “painful” scratching which relieves the feeling of itch, and that morphine administration reduces pain while increasing itch [3]. The intersection between the two sensations translates to potential treatment as well: chronic itch, for example, can be treated by medications similar to chronic pain [2]. Researching the interplay between itch and pain can help illuminate the pathophysiology of itch and how it is perceived as a sensation different from pain, and consequently lead to a better understanding of treating itch.
Currently, there are numerous models and theories proposed to explain this overlap, however, there is no consensus amongst itch researchers on which model(s) may best explain the relationship between pain and itch. This review will be an overview of the various models of itch transduction and perception and how they have evolved with the accumulation of new research. It will also cover the basic mechanisms of itch at the level of the periphery and spinal cord and how it interacts with pain.
Overview of Itch Mechanisms
Itch Activation at the Level of the Epidermis
Pruriceptors are neurons capable of detecting itch; these can be activated by either mechanical stimuli, a scratchy fabric for instance, or chemical stimuli, such as poison ivy. For simplicity, and as the chemical pathway is currently better understood, the paper will focus on chemical itch from here onwards. Similar to other somatosensory neurons, the cell bodies of the primary pruriceptive neurons reside in the dorsal root ganglion (DRG), close to the spinal cord, with axons stretching to both the periphery and the spinal cord [4, 5]. Unlike other sensory modalities, itch is specific to the outermost epidermis only, as opposed to pain, which can be felt in the muscle and bone. The pruriceptors’ branched sensory nerve endings which terminate in the epidermis are studded with membrane receptors activated by various “itchy” mediators [4]. The receptors differ in the mediators they respond to but can be broadly grouped into histamine receptors, serotonin receptors, G Protein-coupled receptors (GPCRs), toll-like receptors (TLRs), or cytokine and chemokine receptors [4,5].
Once acute itch is triggered by an irritant, keratinocytes, mast cells, and immune cells release chemical mediators which trigger vasodilation, inflammation, and the arrival of more immune cells to clear the irritant. The chemical mediators can include histamine, serotonin, proteases, cytokines, and chemokines, each of which is associated with a certain receptor [4]. The activation of itch from internal factors in disease differs from acute itch in that it is instead dependent on unknown mediators in the bloodstream from drugs or diseased organs [4]. Despite the origin of the chemical mediators, however, once released they bind to the receptors on the free nerve endings and activate them. The receptors then depend on various ion channels to depolarize the pruriceptor neuron which conveys the sensory information to the spinal cord via its axon [4, 5].
Itch Transmission to the Spinal Cord
The pruriceptive DRG neurons’ axon also ends in the spinal dorsal horn. These then synapse onto interneurons in the spinal cord which connect to projection neurons that carry the sensory information to the brain. The interneurons are important for transmission as well as modulation of itch via excitatory and inhibitory synapses [4, 5, 6]. Electrophysiological responses to itch stimuli in primates have identified the projection neurons as belonging to the spinothalamic tract, which carries axons to the thalamus. This tract also conveys pain and temperature and is consequently an area of itch interaction with other modalities [5, 7]. In addition to interneurons, descending modulation in the spinal cord can also regulate itch. After applying a cervical cold block to mice – activity of the upper cervical spinal cord level was essentially stopped – mice were unable to relieve itch and decrease neuronal firing when the lumbar spinal cord neurons below were stimulated by an itchy substance. This suggests that there is some level of descending modulation that was disrupted when the upper spinal cord was damaged [8].
Areas of Itch and Pain Interaction
Having briefly discussed the pathways for itch perception, it is important to note how often it converges with that of pain. Firstly, pruriceptors are in fact pruriceptive nociceptive neurons, meaning they are a subset of nociceptors, or pain-sensitive neurons. Although there are many non-pruriceptive nociceptors (neurons sensitive to pain but not itch), studies have pointed towards most pruriceptors being stimulated by pain as well as itch [1, 2]. One method of explaining this convergence is the expression of TRPV1 ion channels in pruriceptors. Although these are important for detecting itch, it is also expressed in nociceptors, and is stimulated by the classic pain stimulus found in peppers, capsaicin [4].
The relationship between itch and pain continues to the spinal cord. As mentioned, the spinothalamic tract (STT) is of special interest in understanding the distinction between itch and pain, as both sensations traverse the same pathway. Transecting the anterolateral funiculus where the tract ascends has eliminated sensitivity to itch, pain, and temperature, establishing the common usage of the tract by these sensations [6]. Electrophysiological recordings of primate STT neurons when given different types of sensory stimuli also revealed that two thirds of the nociceptors were sensitive to itch stimuli as well as pain, again highlighting the apparent overlap between itch and pain in the spinal cord [9].
The relationship between itch and pain is best understood as antagonistic. Recordings of STT pruriceptive neurons showed that after being stimulated by histamine (itch/pruritic stimuli) the neuronal firing decreased when the skin was scratched. However, the same neuron increased firing after scratching in response to capsaicin. Although being activated by both pain and itch stimuli, the difference in response to scratching suggests an antagonistic relationship between pruriceptive and nociceptive neurons via inhibitory interneurons [6].
The intersection between pain and itch raises the question of the brain’s perception of pain and itch as distinct in the presence of much overlap. There are numerous theories and models attempting to explain the nature of this relationship, which will be overviewed in the following sections.
Classical Models of Itch and Pain Discrimination
Intensity Model
Given observations on the overlaps between itch and pain, itch was first theorized to be a subset of pain in the intensity model. This postulates that polymodal neurons (sensitive to many modalities) differentiate between itch and pain through patterns of firing or “intensity” due to weak or strong stimulation [1, 4, 6, 10]. The model was tested by delivering electrical pulses to the skin that varied in frequency. Although the results seemingly disproved the theory as it only increased the intensity of itch felt, rather than transforming it to pain, the theory has not yet been discounted [6]. Itch stimuli has been shown to trigger lower firing rates compared to painful stimuli in both peripheral and STT neurons, suggesting that firing rates do have some role in itch perception [6, 9]. Furthermore, both itch and pain stimuli give rise to “bursting” patterns of action potentials, and the interburst interval is shorter in response to capsaicin/pain. This suggests some level of temporal coding, when information is coded based on the timing of action potentials or intervals between them. This aligns with the intensity model as a polymodal neuron could code for itch and pain depending on the rate of action potentials or their intervals [9].
The intensity model’s basic principle lies in neurons activated by both pain and itch, and seemingly aligned with the previously mentioned research identifying pruriceptors as a subset of nociceptors and activated by both pain and itch. However, the discovery of itch-specific neurons further complicated the validity of the model, lending support to the labeled line model instead.
Labeled Line or Specificity Theory
Labeled line refers to the idea that there exists a specific, separate “line” or neural pathway devoted to the sensation of itch – the opposite of the intensity model’s polymodal neurons. As early as the 1800s, researchers discovered there are specific spots on the skin which are activated by different sensory modalities: coolness, heat, pain, etc., giving rise to the labeled line theory. Recent electrophysiological studies have supported this for different sensations through establishing the presence of sensory fibers and spinal relay neurons tuned to only one sensory modality [11].
The labeled line theory’s validity for itch was confirmed by the presence of itch specific neurons. GRPR3+ neurons in the spinal cord were identified that differed from STT neurons in that they carried purely itch information [3, 12]. This was evident as when these neurons were treated with a toxin, not only was there loss of itch behavior (scratching), there was no change in pain behavior (wiping) [12]. The discovery of these itch specific neurons was emphasized by the consequent discovery of MrgprA3+ neurons in the dorsal horn which were itch specific as well; their deletion also resulted in loss of itch behavior only [7]. Furthermore, the neurons gave rise to purely itch behavior regardless of the nature of the stimulus – precisely as predicted by the labeled line [7]. These discoveries gave significant support to the labeled line theory, yet the presence of itch neurons activated by pain remained a dilemma.
Modified Models of Itch and Pain
The theories of intensity and labeled line represent the two ends of the spectrum in understanding pain signalling – the first depends on polymodal neurons, and the latter on itch specific neurons. The discovery of neurons that fall under both complicate their validity, and suggest that an accurate model should include neurons sensitive to both itch and pain while capable of differentiating between the two [1].
Spatial Contrast Model
Spatial models expand on the intensity model, and do not require itch and pain specific neurons. It proposes that itch is felt in “spatial contrast,” or when a small population of nociceptors are activated, and pain is felt when a larger population is activated due to a stronger stimulus [6,10]. In a study, it was observed that a spicule (small pointed end) of both histamine (itch stimuli) and capsaicin resulted in itch sensation, yet an injection of only capsaicin resulted in pain activation [13]. This could be explained by the spatial contrast theory in that the spicule activated a small number of nociceptors, resulting in itch, whereas the more widespread injection stimulated a larger number of nociceptors, resulting in pain.
According to the model, a small number of even non-pruriceptive nociceptors activated should result in itch, eliminating the need for a labeled line. However, there remains an obstacle in this model as well – there was no decrease of itch sensation relative to pain when the area of exposure to stimuli increased, although the model predicts this should in theory activate a greater number of receptors [6, 13].
Selectivity Theory and Population Coding
The population coding theory – also known as the selectivity theory – modifies the labeled line, proposing that although there are specific sensory labeled lines, the antagonistic interaction between them shapes perception of itch. It takes into account the overlap between nociceptors and pruriceptors as well as pain’s inhibition of itch, proposing that pruriceptors are a smaller subset of nociceptors and are linked to them by inhibitory interneurons [1,11]. Theoretically, activation of the larger nociceptive population – including pruriceptors – is felt as pain, as the activation of the pain neurons “masks” the sensation of itch. Yet if only the smaller itch specific subset is activated, this is felt as purely itch, as there is no activation, and consequently no inhibition from the nociceptive neurons [1, 11, 14].
There have been numerous studies that appear to support this hypothesis. In one, the vesicular glutamate transporter VGLUT2 was deleted from DRG nociceptive neurons, affecting their ability to signal. This resulted in spontaneous itch in mice along with a decrease in pain behavior and, importantly, itch behavior resulting from capsaicin injections [14]. These results were paralleled in another study where blocking pruriceptors had no effect on pain, yet deleting TRPV1 in a group of nociceptive neurons led to capsaicin to be perceived as itch [15]. These two studies suggest groups of nociceptors are involved in inhibiting and masking itch, as deleting their receptors results in itch signaling instead, supporting the population coding theory.
It is also necessary to identify an inhibitory neuron to explain the antagonistic relationship between the nociceptors and pruriceptors; Bhlhb5 neurons are one such interneuron. When Bhlhb5 was knocked out in mice, there was increased itch behavior that ultimately resulted in lesions from itching and licking [16]. This suggests that the interneuron, and perhaps other interneurons as well, are responsible for inhibiting and regulating itch, further bolstering the support for the population coding model.
Gate Control and Leaky Gate Model
The gate control theory hypothesizes that nociceptive transmission neurons in the spinal cord receive input from both nociceptive primary neurons, and Aβ fibers: primary neurons attuned to non-nociceptive stimuli such as touch. These Aβ fibers in turn inhibit the nociceptive neurons via interneurons, effectively creating a “gate” that can halt transmission of pain or itch [10]. The previously mentioned Bhlhb+ interneurons support this gate control model as well [10, 16].
This model was recently further refined into the “leaky gate” theory. This builds on the intensity theory and modifies the gate control theory by substituting Grp+ neurons in the role of Aβ fibers. Grp+ spinal cord neurons receive strong input from pain sensory neurons and weak input from itch specific neurons, coding for itch in an intensity dependent manner and inhibiting pain. This model is different from gate control in that it lets weak pain signals “leak” through while suppressing strong pain signals to prevent an overwhelming pain sensation. When strongly activated by pain, these interneurons inhibit pain, whereas due to weak activation from itch, it does not inhibit pain [10]. This model is able to explain the phenomenon that itch is often accompanied with a prickly, burning pain: it proposes that itch is not strong enough to inhibit pain sensation, resulting in a weak pain sensation accompanying itch [10].
Conclusion
A few of the major theories of itch perception have been discussed in an attempt to illuminate how itch is attenuated by the presence of pain in an inverse relationship. The intensity theory and the labeled line theory are both supported by the presence of polymodal neurons and itch specific neurons, respectively. However, given their opposing views, the accuracy of both theories is undermined by support for the other; this indicates the need for a model that is able to reconcile itch specificity with neurons attuned to both itch and pain.
The following models attempted to ease the apparent discord between the two previous models. The spatial model expands on the intensity model while providing a possible mechanism by which pain and itch could be felt from the same population of neurons. On the other hand, the population coding model expands on itch specific neurons of the labeled line while accommodating the inverse relationship between itch and pain. Lastly, the leaky gate model combines aspects of both intensity and selectivity theories.
These theories attempt to explain itch and pain crosstalk; the importance of understanding this relationship is seen in both acute and chronic itch pathophysiology in cases of crosstalk dysfunction. The previously discussed Bhlhb+ neurons are a prime example of the consequences of impaired itch and pain interaction [2, 16]. Research has shown that knocking out these interneurons – thereby severing the connection between itch and pain – results in chronic itch-like behavior such as lesions from scratching [16]. This suggests that chronic itch may result from uninhibited, unregulated itch when pain is no longer permitted to suppress itch [2, 16].
This example highlights the importance of the application of the interaction between pain and itch. Not only does understanding the intersection between the two sensations provide a better understanding of itch mechanisms, the very intersection itself has an important role in itch pathophysiology, of which there is much that is still unknown. With the advent of new discoveries of new aspects of the itch pathway, these current models will continue to develop.
References:
- Patel KN, Dong X. 2010. An Itch To Be Scratched. Neuron. 68(3):334-339. doi: 10.1016/j.neuron.2010.10.018.
- Liu T, Ji RR. 2013. New insights into the mechanisms of itch: are pain and itch controlled by distinct mechanisms?. Pflugers Arch. 465(12):1671-1685. doi:10.1007/s00424-013-1284-2
- Barry DM, Munanairi A, Chen ZF. 2018. Spinal Mechanisms of Itch Transmission. Neurosci Bull. 34(1):156-164. doi:10.1007/s12264-017-0125-2
- Dong X, Dong X. 2018. Peripheral and Central Mechanisms of Itch. Neuron. 98 (3):482-494, doi: 10.1016/j.neuron.2018.03.023.
- Lay M, Xinzhong D. Neural Mechanisms of Itch. Annual Review of Neuroscience, 43:187-205. doi: 10.1146/annurev-neuro-083019-024537
- LaMotte RH, Dong X, Ringkamp M. 2014. Sensory neurons and circuits mediating itch. Nat Rev Neurosci. 15(1):19-31. doi: 10.1038/nrn3641
- Han L, Ma C, Liu Q, Weng H, Cui Y, Tang Z, Hao-Jui Weng, Yiyuan Cui, Zongxiang Tang, Yushin Kim, Hong Nie, Lintao Qu, Kush N Patel, Zhe Li, Benjamin McNeil, Shaoqiu He, Yun Guan, Bo Xiao, Robert H LaMotte & Xinzhong Dong .2013. A subpopulation of nociceptors specifically linked to itch. Nat Neurosci 16, 174–182. doi: 10.1038/nn.3289
- Carstens E, Iodi MC, Akiyama T, Davoodi A, Nagamine M. 2018. Opposing effects of cervical spinal cold block on spinal itch and pain transmission, Itch. 3(3):16 doi: 10.1097/itx.0000000000000016
- Davidson S, Zhang X, Khasabov SG, Moser HR, Honda CN, Simone DA, Giesler GJ Jr. 2012. Pruriceptive spinothalamic tract neurons: physiological properties and projection targets in the primate. J Neurophysiol. 108(6):1711-23. doi: 10.1152/jn.00206.2012.
- Sun S, Xu Q, Guo C, Guan Y, Liu Q, Dong X. 2017. Leaky Gate Model: Intensity-Dependent Coding of Pain and Itch in the Spinal Cord. Neuron. 93(4):840-853.e5. doi:10.1016/j.neuron.2017.01.012
- Ma Q. 2010. Labeled lines meet and talk: population coding of somatic sensations. J Clin Invest. 120(11):3773-3778. doi:10.1172/JCI43426
- Sun YG, Zhao ZQ, Meng XL, Yin J, Liu XY, Chen ZF. 2009. Cellular basis of itch sensation. Science. 325(5947):1531-1534. doi:10.1126/science.1174868
- Sikand P, Shimada SG, Green BG, LaMotte RH. 2009. Similar itch and nociceptive sensations evoked by punctate cutaneous application of capsaicin, histamine and cowhage. Pain, 144(1-2), 66–75. https://doi.org/10.1016/j.pain.2009.03.001
- Liu Y, Abdel Samad O, Zhang L, Duan B, Tong Q, Lopes C, Ji RR, Lowell BB, Ma Q. 2010. VGLUT2-dependent glutamate release from nociceptors is required to sense pain and suppress itch. Neuron, 68(3), 543–556. https://doi.org/10.1016/j.neuron.2010.09.008
- Roberson DP, Gudes S, Sprague JM, Patoski HA, Robson VK, Blasl F, Duan B, Oh SB, Bean BP, Ma Q, Binshtok AM, Woolf CJ. 2013. Activity-dependent silencing reveals functionally distinct itch-generating sensory neurons. Nature neuroscience 16(7):910-8. doi: 10.1038/nn.3404.
- Ross SE, Mardinly AR, McCord, AE, Zurawski J, Cohen S, Jung C, Hu L, Mok SI, Shah A, Savner EM, Tolias C, Corfas R, Chen S, Inquimbert P, Xu Y, McInnes RR, Rice FL, Corfas G, Ma Q, Woolf CJ, Greenberg ME. 2010. Loss of inhibitory interneurons in the dorsal spinal cord and elevated itch in Bhlhb5 mutant mice. Neuron, 65(6), 886–898. https://doi.org/10.1016/j.neuron.2010.02.025
Among Virions
By Jordan Chen, Biochemical Engineering ‘24
What are viruses? Miniscule packages of protein and genetic material, smaller than all but the smallest cells, relatively simple structures on the boundaries of what we consider living. Undetectable to the human eye, these invisible contagions are rarely on the minds of the average person, occupying a semantic space in public consciousness more often than they are understood for their material reality. Stories are more likely to be described as “viral” than an actual virus, yet when the COVID-19 pandemic washed over the world at the end of 2019, the public suddenly had to confront that which was seemingly abiotic, simple, and small. However, the impact of the COVID-19 pandemic exceeded that unassuming material reality. With the shuttering of the global economy, mass death, political crisis, confusion, hysteria, and science without immediate answers, it’s become clear that the sum of COVID-19’s viral components is much more than the whole.
To emphasize this idea in the piece, coronavirus virions are depicted as massive and detailed larger than earth bodies, in a vital bloody red, surrounding and overwhelming the relatively simply shaded globe. What was formerly small, simple, and nonliving, can now be dramatically understood as larger than life, having created complex predicaments, and having taken on a life of its own in its assault against the world. This digital artwork was created in Blender.
Reproductive and Developmental Health Effects of PFAS on Animal Models: A Review of Current Literature
By Anna Maddison, Environmental Toxicology ‘21, Janaé Bonnell, Environmental Toxicology ‘22, Dr. Michele La Merrill
Authors’ Note: This literature review was conducted for the Office of Environmental Health Hazard Assessment in the California Environmental Protection Agency under a contract issued to Dr. Michele La Merrill. We wanted to understand the current research on the reproductive and developmental toxicity of PFHxS, PFBS, PFHxA, PFHpA, PFNA, PFDA, and ADONA to draw conclusions and make recommendations for future policy and research. It is important to understand the health effects of substances such as PFAS chemicals that are present in our food, water, and consumer products to develop regulatory standards that protect public health.
Abstract
Per- and polyfluoroalkyl (PFAS) chemicals are used in the production of many industrial processes and consumer goods, and they have been widely detected in humans and animals. PFOS and PFOA have been comprehensively studied and are being phased out of use, but there are other understudied PFAS chemicals with effects that should be considered in regulatory affairs regarding public health and safety. In this study, we focus on the reproductive and developmental effects of seven PFAS chemicals: perfluorononanoic acid (PFNA), perfluorohexanoic acid (PFHxA), perfluorohexane sulfonic acid (PFHxS), 4,8-dioxia-3H-perfluorononanoic acid (ADONA), perfluorobutane sulfonic acid (PFBS), perfluoroheptanoic acid (PFHpA), perfluorodecanoic acid (PFDA). This literature review presents the observed reproductive and developmental effects of these chemicals on animal models, which can be used to help establish legislative priorities and draw attention to current gaps in published literature.
Keywords: PFAS, review, animal model, PFBS, PFHxS, PFHpA, PFHxA, PFDA, PFNA, ADONA
Introduction
Poly- and perfluoroalkyl (PFAS) chemicals are widespread synthetic chemicals that are highly mobile, persistent in the environment, and are known to bioaccumulate in humans and animals[1,2]. PFAS chemicals have extensive use due to their unique anti-wetting abilities, as well as their ability to act as a surfactant, a molecule that lowers the surface tension between two liquids[3]. These properties have led to their use in oil- and water-repellent textiles, coatings, and fire-retardant products. PFAS chemicals can also be found in drinking water, production facilities and industries, and many commercial household products[1,4]. Humans are mainly exposed to PFAS through their diet but are unable to metabolize these chemicals in their bodies[5,6].
These chemicals have found use in multiple industries for over 60 years[7]. PFAS production peaked in the 1990s, with PFOS and PFOA being the most popularly used PFAS chemicals. However, after studies linked these chemicals to adverse human health effects, including damage to the immune system and liver, reproductive and developmental harm, hormone disruption, and cancer, the United States had voluntarily phased out their use[1,5,2]. The industry has since shifted to favor PFASs with shorter chains, as these were believed to be less harmful to human health[7,8]. Although no association between chain length and toxicity has been proven, it is still being explored.
To this end, perfluorohexane sulfonic acid (PFHxS), perfluorobutane sulfonic acid (PFBS), perfluorohexanoic acid (PFHxA), perfluoroheptanoic acid (PFHpA), perfluorononanoic acid (PFNA), perfluorodecanoic acid (PFDA), and 4,8-dioxia-3H- perfluorononanoic acid (ADONA) have been increasingly used for industrial purposes as alternatives to PFOS and PFOA[6,8]. These PFAS chemicals have shorter carbon backbone chains, so it is believed they may have less negative health effects than PFOA and PFOS, but this has not been proven. However, their health effects are not as well-explored as those of PFOS and PFOA, thus necessitating new research into the long-term health impacts of exposure to these replacement PFAS chemicals.
Multiple epidemiological studies in humans have suggested that there is an association between PFAS exposure and adverse reproductive and developmental health impacts. After exposure during pregnancy, lower levels of thyroid hormones T3 and thyroxine have been observed in both pregnant women and fetuses, as well as adverse birth outcomes and behavioral effects on children exposed in-utero[6,9]. Some of these PFAS chemicals, such as PFNA, are being detected in both seminal plasma and breast milk of humans[10].
Individuals who are not fully developed may be more vulnerable to PFAS exposure and therefore, more at risk for any toxic effects. The purpose of this literature review is to survey reproductive and developmental effects of PFAS exposure to inform on potential literary gaps and future regulatory priorities.
Methods
Search Procedure
The research for this literature review was conducted by systematically choosing articles discovered through the search engine PubMed. The initial database of articles was created from searching the abbreviated forms of the chemical names (PFHxS, PFBS, PFHxA, PFHpA, PFNA, PFDA, ADONA) in PubMed using the filter “Other Animals” (Table 1). Only papers in English were considered for inclusion. An exception was made for ADONA due to our search yielding an excess of papers written by an author by that name. Instead the search term “ADONA NOT adona [author]” was used. Even with the reduced search, many of the results did not include the PFAS chemical ADONA, and subsequently, were not included.
Table 1: Contains a list of searches and number of results yielded for each one.
Search Date | Search Term(s) | Number of Results |
April 15th, 2020 | PFHxS | 124 |
April 25th, 2020 | PFBS | 78 |
April 25th, 2020 | PFHxA | 54 |
April 25th, 2020 | PFHpA | 29 |
April 25th, 2020 | PFNA | 189 |
April 25th, 2020 | PFDA | 198 |
April 26th, 2020 | PFHxS | 125 |
May 12th, 2020 | PFHpA | 30 |
May 13th, 2020 | PFDA | 199 |
May 15th, 2020 | “ADONA NOT adona [author]” | 14 |
May 29th, 2020 | PFDA | 200 |
Study Selection
The titles and abstracts of each article were scanned for relevance to reproductive toxicity. This includes in vitro studies on isolated cells, different toxicological effects based on sex, responses affecting reproductive organs, and developmental effects in offspring. To limit the scope, this excluded human studies, bioconcentration studies that did not specify reproductive organs or unique developmental patterns, wildlife studies, and studies focused on other organ systems not in the context of reproduction or development. Additionally, we chose to exclude studies which used a mixture of chemicals or in which the PFAS chemical was analyzed as a metabolite of a parent chemical. This was due to the fact that it is uncertain which chemical actually caused an effect. Relevant articles were examined in depth to determine significant toxicological effects of the PFAS chemicals. The number of relevant articles in comparison to the total articles which arose from our search can be seen in Table 2. Other notable responses, from papers which included reproductive effects, were denoted in our accompanying spreadsheet. Due to time constraints, the results for PFDA were summarized with less depth and were instead included as an appendix.
Table 2: Contains the number of resulting studies chosen for inclusion in this review.
Chemical | Articles Used in Our Research |
Perfluorononanoic Acid PFNA | 17 |
Perfluorohexanoic Acid PFHxA | 5 |
Perfluorohexane Sulfonic Acid PFHxS | 11 |
4,8-3H-Perfluorononanoic Acid ADONA | 1 |
Perfluorobutane Sulfonic Acid PFBS | 15 |
Perfluoroheptanoic Acid PFHpA | 2 |
Perfluorodecanoic Acid PFDA | 16 |
Results
PFNA
Seventeen studies contained relevant reproductive and/or developmental effects of PFNA exposure. All of these studies except for one, which dosed Xenopus laevis (African clawed toad, African claw-toed frog or the platanna), examined the effects of PFNA exposure on Danio rerio (zebrafish), Rattus (rats), or Mus (mice). These studies are compiled in Supplementary Table 1 (ST1).
PFNA exposure in Danio rerio caused embryo disfigurement and altered motion patterns, as well as other reproductive and developmental effects. In recently fertilized eggs, PFNA exposure resulted in an increase in malformation rate[6], specifically, in the rate of ventricular edema[19]. Studies also showed correlation between PFNA exposure and locomotion: Danio rerio exposed as embryos travelled less distance [11][13][6], their activity level increased[24] [13], they bumped into the mirror more[13], their startle response and burst activity increased[6], the amount of time they spent in the middle of the water, and their velocity changed[13][11]. Additionally, exposure to PFNA caused reproductive effects such as an increase in the number of opaque embryos[19][, a decrease in hatching rate[19][15], a decrease in the number of eggs in females[15], and an increase in yolk sac area[11]. Observed developmental effects included a decrease in body length[13], abnormally enlarged follicles in the thyroid, and increased T3 hormone levels[18].
In Mus and Rattus, the most observed reproductive effects occurred in the testis. In Rattus, cell viability in Sertoli[12] and testicular[23] cells decreased, DNA damage in testicular cells increased[23], vacuoles formed in the Sertoli cells[12], the number of germ cells that degenerated or were TUNEL-positive increased[12][20], and the percentage of apoptotic cells in the testis increased[20]. In Mus, intratesticular and serum levels of testosterone, testicular glucose level, and testicular lactate concentration decreased[14][10]. Also in Mus, seminiferous tubules had intraepithelial vacuolation where small cavities formed in the tubules, marginal condensation of chromatin in round spermatids, and giant cells and exfoliation of germ cells in the lumen of the tubules[14]. Reproductive effects in mammals exposed to PFNA included reduced prenatal and postnatal survival[16], maternal weight decreased[16][25], and lower birth weight and higher blood pressure in pups[25]. Additionally, there was a sex-specific difference in that serum concentration of PFNA decreased more rapidly in adult females than males[17]. Finally, the developmental effects of PFNA exposure in Mus who had not experienced puberty included a decrease in weight, an increase in absolute and relative liver weight, and hepatocellular hypertrophy[14][10].
In Xenopus laevis, PFNA exposure resulted in increased embryo mortality and malformations including stunted tadpole length, multiple edemas, gut miscoiling, microcephaly in which the offspring had abnormally small heads, and skeletal kinking[22].
PFHxA
Five articles on reproductive and/or developmental effects of PFHxA, which showed statistically significant responses, were found to be relevant to our study. These studies are compiled in Supplementary Table 2 (ST2). Each of the five papers studied a different animal: Danio rerio, Daphnia magna, anuran Xenopus laevis, Mus, and Brachionus calyciflorus. In both Danio rerio and anuran Xenopus laevis embryos, a decrease in body length was observed in the animals exposed to PFHxA[26][28]. In Daphnia magna, reproductive output increased with chronic exposure to PFHxA and mobility decreased with acute exposure to PFHxA[27]. In the Mus, indirect exposure in utero to PFHxA resulted in pups taking longer to open their eyes, a decrease in their body weight, and a lower ratio of liver to body weight[29]. Xenopus also saw liver effects in the form of swollen livers in tadpoles[28. In Brachionus calyciflorus, the rate of population increase decreased, and the mictic ratio, the ratio between eggs that require fertilization and those that do not, and egg size increased[30].
PFHxS
Using the methods described above, fifteen articles examining the effects of PFHxS on Mus, Rattus, Gallus gallus domesticus, and Danio rerio were within the scope of our literature review. These studies are compiled in Supplementary Table 3 (ST3). In the mammals, notable, visible reproductive and developmental effects were observed. In general, male mammals dosed with PFHxS seemed to present more deviations from the control opposed to females. For example, when PFHxS was orally administered or injected via IV, male Rattus took a significantly longer time to expel it from their plasma than female Rattus[38]. Other instances of this trend were apparent when male pups displayed increased anogenital distance[35] and decreased weight gain[36] at more concentrations than females. Other effects of PFHxS in mammals included decreased activity[32] and increased liver and thyroid weight[35] in pups who were respectively dosed neonatally and exposed indirectly in utero as well as directly for two weeks. In Gallus gallus domesticus, PFHxS egg injections decreased pipping success, which is the chick’s ability to break themselves out from their shell, and decreased the mass of embryos[37]. Finally, in Danio rerio embryos an EC50 value was calculated to be 84.5μM using the concentration at which they died or suffered from an adverse effect, defined to be non-inflated swim bladder, pericardial or yolk sac edemas, or scoliosis, as a reference[34]. Altered motion patterns and body lengths were also observed[6][26].
ADONA
Only one article was found that showed reproductive effects of ADONA. This study is shown in Supplementary Table 4 (ST4). Pregnant Rattus norvegicus were exposed to ADONA via oral administration which resulted in a decrease in pup weight, maternal food consumption while pregnant, maternal weight gain, and the number of pups that survived[40]. A higher dosage was abandoned after two days due to death, significant body weight loss, reduced food consumption, decreased activity, dehydration, coldness to touch, pale extremities, rales or rattling sounds in the lungs, ungroomed coat, urine-stained fur, and ptosis or drooping eyelids in the pregnant Rattus[40].
PFBS
Seventy-nine articles resulted from a PubMed search on perfluorobutane sulfonic acid (PFBS) using the above-described methods. Of those seventy-nine articles, fifteen were deemed to be within the scope of this review. These studies are compiled in Supplementary Table 5 (ST5). These studies investigated the effects of PFBS on Mus musculus (mice), Oryzias melastigma (marine medaka), Caenorhabditis elegans, Danio rerio, Rattus norvegicus (rats), Xenopus laevis, and C. riparius (harlequin flies). A multitude of adverse reproductive effects was observed as a result of PFBS exposure. Multiple studies demonstrated that PFBS affects hormone levels in both ICR Mus and Oryzias, generally including a decrease in estrogen levels in all animals and a testosterone decrease in males[7][43]. One study noted that males were experiencing estrogenic changes and females were experiencing antiestrogenic changes as a result of PFBS exposure[43]. PFBS exposure also leads to alterations in levels of follicle-stimulating hormone and progesterone[7][43]. In several egg-producing organisms studied, it was found that overall egg production was significantly decreased[42][43] and that this effect could also occur after several generations of exposure to PFBS[48]. In both Mus and Oryzias, significant decreases in uterus and ovary size were recorded in both exposed organisms[43][9]. These species also had significant changes in the number of follicles and oocytes in various stages after exposure[7][43][9]. Lastly, organisms were observed to have decreased length after exposure to PFBS, an effect that was usually more prominent in males[3][48][49].
First-generation offspring from exposed parents were observed to have changes in hormone levels that would affect growth and development, generally including increases in luteinizing hormone[43][9] and significant alterations in T3 concentration[3][9]. Reduced estrogen levels and elevation of thyroid-stimulating hormone were also observed[9]. The length of diestrus in Mus and Rattus was also significantly increased after parental exposure to PFBS[9][8]. Significant decreases in uterus and ovary size were recorded in the offspring of exposed Mus and Oryzias[43][9]. Mus offspring were also observed to have significant changes in the number of follicles and oocytes in various stages[9]. Furthermore, organismal body weight was observed to be influenced by parental PFBS exposure, although it both increased and decreased in separate experiments[3][8][48]. A study exploring the influence of maternal and paternal dosage on Oryzias offspring observed greater negative impacts on offspring related to paternal exposure to PFBS rather than maternal exposure, such as swimming hyperactivity[44]. Offspring of exposed parents also experienced deformities, such as increased tail and craniofacial malformations in Danio rerio[49]. Lastly, it was observed that PFBS exposure delayed both the age of vaginal opening[9] and preputial separation in Mus and Rattus with parents exposed to PFBS[8].
Of the fifteen studies included, only two focused on the multigenerational effects of PFBS on organismal reproduction and development. PFBS was observed to affect T4 hormone concentration in F2 generation Oryzias after a life-cycle exposure during the F0 generation[3]. In the same species, both the weight of F2 generation eggs, as well as their lipid and protein content, were significantly increased after ancestral exposure during the F0 generation development[43].
PFHpA
A search of PubMed using the above methods yielded thirty results for the chemical PFHpA. Of these thirty results, two were found to be within the scope of this review. These studies are compiled in Supplementary Table 6 (ST6). These reports studied the effects of multiple chemicals, including PFHpA, on Danio rerio and Xenopus laevis via exposure in solution. Both studies are described here due to the limited number of papers. The lowest-observed-adverse-effect levels in the Menger[6] and Kim[28] studies were found to be 89 µM and <0.25 mM (250 μM) renewed daily, respectively. The findings in these studies suggest that PFHpA is both a possible teratogen negatively affecting the embryo or fetus and a developmental toxicant in multiple animal species[28]. A dose-response relationship was exhibited regarding PFHpA dosage and rates of both malformations and mortality in Xenopus embryos[28]. Observed malformations included reduction of body length in 24% of Xenopus tadpoles dosed with 1,000 µM of PFHpA as embryos, as well as enlarged, abnormal livers[28]. However, the observation of reduced tadpole body length was only noted at a dosage of 1,000 µM of PFHpA, which is comparable to the LC50 value in this study, found to be 942.4 µM[28]. There was also evidence of potential behavioral effects in developing organisms. For example, Danio rerio exposed to PFHpA had a significant decrease in swimming distance recorded at the highest dosage[6]. No studies listed in PFHpA searches investigated the reproductive hazard of the chemical.
PFDA
Of the two hundred articles listed for PFDA on PubMed using the above search methods, sixteen studies were considered relevant to be included within this report. These sixteen studies are summarized in Appendix 1 (A1) and a subset of them is highlighted here. Both the viability and maturation of pig oocytes was shown to be negatively impacted by exposure to PFDA[50]. The thyroid was shown to be affected in multiple studies, with thyroid hormone levels being both decreased[59][61][62] and increased[57] in different reports. PFDA also adversely affected the sexual organs of exposed organisms, including the seminal vesicle[56] and seminiferous tubules[60]. In rats, hamsters, and guinea pigs, degeneration of the seminiferous tubules was observed following PFDA exposure[60].
Outside of the 184 remaining studies not included in Appendix 1, three studies stated that PFDA may be estrogen-like in its action. However, these three papers did not contain health endpoints that were within the scope of this report, such as gene expression and carcinogenesis[64][65][66]. These papers are referenced within the sources of this report but were not included within the review of reproductive and developmental health, nor were they included within Appendix 1 (A1).
Discussion
While the toxicity of PFBS, PFHxS, PFHpA, PFHxA, PFDA, PFNA, and ADONA, which are used as substitutes for PFOS and PFOA, is still being investigated, the current body of scientific research suggests that exposure to these PFAS chemicals poses potential reproductive and developmental risk to an organism.
In several species, PFNA exposure resulted in several effects that could interfere with normal procreation and aging systems. Observed deviations from control groups included embryo malformation, offspring mortality, altered behavioral patterns, morphological abnormalities, weight changes, and different hormone levels. There was evidence to suggest that males retain more PFNA than their female counterparts, and several studies suggested that male sex organs were impacted by PFNA exposure. Relative to the other PFAS chemicals studied in this paper, PFNA had a high amount of significant papers with reproductive and developmental effects. This may suggest that it poses a higher risk than some of the other chemicals, but it should be considered in the context that PFNA also had a higher number of search results than the other chemicals and therefore, may just be more well studied. A limitation in these findings that should be considered is the apparent lack of corresponding research on female sexual organs. Also, several effects were not observed to have a dose-dependent response, while others were only seen at lower concentrations.
PFHxA only had five relevant studies and each used a different species as test subjects. Additionally, there were four studies, two used in the results of PFHxA and two not used due to a lack of significant results, which also did their experiments with other PFAS chemicals, and in comparison, individuals dosed with PFHxA had milder, if any, effects. This suggests that PFHxA may have lower reproductive and developmental toxicity than other PFAS chemicals in this paper. This could be taken into consideration when assessing the risk of exposure associated with this chemical.
PFHxS, similar to PFNA, had more toxic effects in males than females. Unlike the studies using PFNA, a majority of these did test both males and females in the same conditions. Exposed males retained a higher serum concentration of PFHxS for longer and displayed changes in anogenital distance and weight at a larger range of dosage concentrations than females.
There was one relevant paper that addressed the reproductive and developmental effects of ADONA exposure. This, coupled with the potential conflict of interest presented by the funding, makes it impossible to draw any conclusions regarding the toxicity of this chemical. Even so, effects were observed from exposure to ADONA. These included changes in weight, mortality rate, and food consumption. To further understand the reproductive and developmental toxicity of ADONA, further research is necessary.
Multiple species demonstrated adverse reproductive and developmental health outcomes after exposure to PFBS. Alterations to hormone levels and morphological abnormalities were observed following PFBS dosage. Also, PFBS was seen to potentially influence hormonal sex changes in exposed fish. Several studies emphasized the impacts PFBS exposure may have on offspring. The above changes were seen in offspring after parental exposure, as well as alterations to egg development and the size of female reproductive organs. It was also noted that paternal exposure to PFBS tends to more negatively impact the health of offspring than maternal exposure does. Compared to other chemicals included within this report, PFBS had a relatively high number of studies that met the requirements for inclusion.
Only two relevant studies were found regarding PFHpA, each using a different test species. These studies investigated the developmental effects of PFHpA on organisms exposed as embryos or tadpoles. Findings suggested that PFHpA may be teratogenic and toxic to developing organisms based on resulting morphological abnormalities and behavioral alterations in exposed organisms. However, no studies were found to investigate the reproductive impacts of PFHpA exposure, leading to a gap in the available research on this chemical.
The studies included on PFDA cover its effect on cell viability, hormone levels, and sex organs, as well the potential developmental toxicity and teratogenicity of PFDA exposure. However, within these studies, there are limitations. Multiple studies did not include information on the age at which organisms, usually Rattus, were dosed, making it more difficult to fully comprehend the effects of PFDA on stages of animal growth. Compared to several of the chemicals included in this paper, PFDA has a relatively higher number of papers that met the criteria for inclusion. Studies have been conducted on this chemical since the 1980s, far preceding work on some of the other chemicals in this report. Furthermore, while the effects of PFDA on hormones and the thyroid have been investigated in several studies, little work appears to have been done on the multigenerational and offspring effects of PFDA. Lastly, five of the sixteen studies investigated the effects of PFDA only on males, leaving further information on female-specific effects to be desired. Both multigenerational and female-specific studies could be considered potential avenues for further research.
Overall, these PFAS chemicals have demonstrated that they may have potential for reproductive and developmental health effects, and their effects on humans should be investigated to ascertain human risk.
Conclusion
The objective of the present study was to compile and summarize the toxic effects of different PFAS chemicals on the reproduction and development of animals in controlled settings. While there are variations in the species used, as well as the method in which they were exposed and the concentration tested, exposure to all seven PFAS chemicals impacted aspects of development, and six had effects on reproduction. These effects should be considered in designing additional research on the outcomes of PFAS exposure and in assessing the risk of these chemicals on living organisms.
Acknowledgements
This work was conducted under California Environmental Protection Agency, Office of Environmental Health Hazard Assessment contract 17-E0024. The authors appreciate the support of Dr. David Furlow, professor of Neurobiology, Physiology, and Behavior and University Honors Program Director at University of California, Davis, and Dr. Sarah Elmore at the Office of Environmental Health Hazard Assessment.
Abbreviations
DPF◇ | days post-fertilization |
E2⛊ | estrogen/estradiol |
FSH╋ | follicle stimulating hormone |
GD⊕ | gestation day |
GnRH◬ | Gonadotropin-releasing hormone |
HPF▽ | hours post-fertilization |
KT-11⌧ | 11-keto-testosterone |
LH⋕ | luteinizing hormone |
P4 | progesterone |
PFAA✿ | perfluoroalkyl acids |
PND⋈ | postnatal day |
PPD⤮ | postpartum day |
T⌓ | testosterone |
T3⍙ | 3,3’,5-triiodothyronine |
T4⌗ | thyroxine |
TBG‡ | thyroxine-binding globulin |
TSHↀ | thyroid-stimulating hormone |
References
- US EPA, O. (2016, March 30). Basic information on pfas [Overviews and Factsheets]. US EPA. https://www.epa.gov/pfas/basic-information-pfas
- Pelch, K. E., Reade, A., Wolffe, T. A. M., & Kwiatkowski, C. F. (2019). PFAS health effects database: Protocol for a systematic evidence map. Environment International, 130, 104851. https://doi.org/10.1016/j.envint.2019.05.045
- Chen, L., Hu, C., Tsui, M. M. P., Wan, T., Peterson, D. R., Shi, Q., Lam, P. K. S., Au, D. W. T., Lam, J. C. W., & Zhou, B. (2018). Multigenerational Disruption of the Thyroid Endocrine System in Marine Medaka after a Life-Cycle Exposure to Perfluorobutanesulfonate. Environmental Science and Technology, 52(7), 4432–4439. https://doi.org/10.1021/acs.est.8b00700
- Lau, C. (2015). Perfluorinated compounds: An overview. In J. C. DeWitt (Ed.), Toxicological Effects of Perfluoroalkyl and Polyfluoroalkyl Substances (pp. 1–21). Springer International Publishing. https://doi.org/10.1007/978-3-319-15518-0_1
- Kingsley, S. L., Eliot, M. N., Kelsey, K. T., Calafat, A. M., Ehrlich, S., Lanphear, B. P., Chen, A., & Braun, J. M. (2018). Variability and predictors of serum perfluoroalkyl substance concentrations during pregnancy and early childhood. Environmental Research, 165, 247–257. https://doi.org/10.1016/j.envres.2018.04.033
- Menger, F., Pohl, J., Ahrens, L., Carlsson, G., & Örn, S. (2020). Behavioural effects and bioconcentration of per- and polyfluoroalkyl substances (PFASs) in zebrafish (Danio rerio) embryos. Chemosphere, 245, 125573. https://doi.org/10.1016/j.chemosphere.2019.125573
- Cao, X. Yuan, Liu, J., Zhang, Y. Jie, Wang, Y., Xiong, J. Wei, Wu, J., & Chen, L. (2020). Exposure of adult mice to perfluorobutanesulfonate impacts ovarian functions through hypothyroxinemia leading to down-regulation of Akt-mTOR signaling. Chemosphere, 244, 125497. https://doi.org/10.1016/j.chemosphere.2019.125497
- Lieder, P. H., York, R. G., Hakes, D. C., Chang, S. C., & Butenhoff, J. L. (2009). A two-generation oral gavage reproduction study with potassium perfluorobutanesulfonate (K+PFBS) in Sprague Dawley rats. Toxicology, 259(1–2), 33–45. https://doi.org/10.1016/j.tox.2009.01.027’
- Feng, X., Cao, X., Zhao, S., Wang, X., Hua, X., Chen, L., & Chen, L. (2017). Exposure of pregnant mice to perfluorobutanesulfonate causes hypothyroxinemia and developmental abnormalities in female offspring. Toxicological Sciences, 155(2), 409–419. https://doi.org/10.1093/toxsci/kfw219
- Singh, S., & Singh, S. K. (2019b). Acute exposure to perfluorononanoic acid in prepubertal mice: Effect on germ cell dynamics and an insight into the possible mechanisms of its inhibitory action on testicular functions. Ecotoxicology and Environmental Safety, 183, 109499. https://doi.org/10.1016/j.ecoenv.2019.109499
- Jantzen, C. E., Annunziato, K. A., Bugel, S. M., & Cooper, K. R. (2016). PFOS, PFNA, and PFOA sub- lethal exposure to embryonic zebrafish have different toxicity profiles in terms of morphometrics, behavior and gene expression. Aquatic Toxicology, 175, 160–170. https://doi.org/10.1016/j.aquatox.2016.03.026
- Feng, Y., Fang, X., Shi, Z., Xu, M., & Dai, J. (2010). Effects of PFNA exposure on expression of junction-associated molecules and secretory function in rat Sertoli cells. Reproductive Toxicology, 30(3), 429–437. https://doi.org/10.1016/j.reprotox.2010.05.010
- Jantzen, C. E., Annunziato, K. M., & Cooper, K. R. (2016). Behavioral, morphometric, and gene expression effects in adult zebrafish (Danio rerio) embryonically exposed to PFOA, PFOS, and PFNA. Aquatic Toxicology, 180, 123–130. https://doi.org/10.1016/j.aquatox.2016.09.011
- Singh, S., & Singh, S. K. (2019a). Prepubertal exposure to perfluorononanoic acid interferes with spermatogenesis and steroidogenesis in male mice. Ecotoxicology and Environmental Safety, 170, 590–599. https://doi.org/10.1016/j.ecoenv.2018.12.034
- Zhang, Sheng, Wang, Zhang, Dai. “Zebrafish Reproductive Toxicity Induced by Chronic Perfluorononanoate Exposure.” Aquatic Toxicology, June 2016, www.sciencedirect.com/science/article/pii/S0166445X16300959?via=ihub
- Das, K. P., Grey, B. E., Rosen, M. B., Wood, C. R., Tatum-Gibbs, K. R., Zehr, R. D., Strynar, M. J., Lindstrom, A. B., & Lau, C. (2015). Developmental toxicity of perfluorononanoic acid in mice. Reproductive Toxicology, 51, 133–144. https://doi.org/10.1016/j.reprotox.2014.12.012
- Tatum-Gibbs, K., Wambaugh, J. F., Das, K. P., Zehr, R. D., Strynar, M. J., Lindstrom, A. B., Delinsky, A., & Lau, C. (2011). Comparative pharmacokinetics of perfluorononanoic acid in rat and mouse. Toxicology, 281(1), 48–55. https://doi.org/10.1016/j.tox.2011.01.003
- Liu, Y., Wang, J., Fang, X., Zhang, H., & Dai, J. (2011). The thyroid-disrupting effects of long-term perfluorononanoate exposure on zebrafish (Danio rerio). Ecotoxicology, 20(1), 47–55. https://doi.org/10.1007/s10646-010-0555-3
- Liu, H., Sheng, N., Zhang, W., & Dai, J. (2015). Toxic effects of perfluorononanoic acid on the development of Zebrafish (Danio rerio) embryos. Journal of Environmental Sciences, 32, 26–34. https://doi.org/10.1016/j.jes.2014.11.008
- Feng, Y., Shi, Z., Fang, X., Xu, M., & Dai, J. (2009). Perfluorononanoic acid induces apoptosis involving the Fas death receptor signaling pathway in rat testis. Toxicology Letters, 190(2), 224–230. https://doi.org/10.1016/j.toxlet.2009.07.020
- Zheng, X.-M., Liu, H.-L., Shi, W., Wei, S., Giesy, J. P., & Yu, H.-X. (2012). Effects of perfluorinated compounds on development of zebrafish embryos. Environmental Science and Pollution Research, 19(7), 2498–2505. https://doi.org/10.1007/s11356-012-0977-y
- Kim, M., Son, J., Park, M. S., Ji, Y., Chae, S., Jun, C., Bae, J.-S., Kwon, T. K., Choo, Y.-S., Yoon, H., Yoon, D., Ryoo, J., Kim, S.-H., Park, M.-J., & Lee, H.-S. (2013). In vivo evaluation and comparison of developmental toxicity and teratogenicity of perfluoroalkyl compounds using Xenopus embryos. Chemosphere, 93(6), 1153–1160. https://doi.org/10.1016/j.chemosphere.2013.06.053
- Lindeman, B., Maass, C., Duale, N., Gützkow, K. B., Brunborg, G., & Andreassen, Å. (2012). Effects of per- and polyfluorinated compounds on adult rat testicular cells following in vitro exposure. Reproductive Toxicology, 33(4), 531–537. https://doi.org/10.1016/j.reprotox.2011.04.001
- Ulhaq, M., Örn, S., Carlsson, G., Morrison, D. A., & Norrgren, L. (2013). Locomotor behavior in zebrafish (Danio rerio) larvae exposed to perfluoroalkyl acids. Aquatic Toxicology, 144–145, 332–340. https://doi.org/10.1016/j.aquatox.2013.10.021
- Rogers et al. “Elevated Blood Pressure in Offspring of Rats Exposed to Diverse Chemicals During Pregnancy.” Toxicological Sciences, Society of Toxicology, Nov. 2013, academic.oup.com/toxsci/article/137/2/436/1675113
- Annunziato, K. M., Jantzen, C. E., Gronske, M. C., & Cooper, K. R. (2019). Subtle morphometric, behavioral and gene expression effects in larval zebrafish exposed to pfhxa, pfhxs and 6:2 ftoh. Aquatic Toxicology (Amsterdam, Netherlands), 208, 126–137. https://doi.org/10.1016/j.aquatox.2019.01.009
- Barmentlo, S. H., Stel, J. M., van Doorn, M., Eschauzier, C., de Voogt, P., & Kraak, M. H. S. (2015). Acute and chronic toxicity of short chained perfluoroalkyl substances to Daphnia magna. Environmental Pollution, 198, 47–53. https://doi.org/10.1016/j.envpol.2014.12.025.
- Kim, M., Park, M. S., Son, J., Park, I., Lee, H.-K., Kim, C., Min, B.-H., Ryoo, J., Choi, K. S., Lee, D.-S., & Lee, H.-S. (2015). Perfluoroheptanoic acid affects amphibian embryogenesis by inducing the phosphorylation of ERK and JNK. International Journal of Molecular Medicine, 36(6), 1693–1700. https://doi.org/10.3892/ijmm.2015.2370
- Iwai, H., & Hoberman, A. M. (2014). Oral (Gavage) combined developmental and perinatal/postnatal reproduction toxicity study of ammonium salt of perfluorinated hexanoic acid in mice. International Journal of Toxicology, 33(3), 219–237. https://doi.org/10.1177/1091581814529449
- Iwai, H., Hoberman, A. M., Goodrum, P. E., Mendelsohn, E., & Anderson, J. K. (2019). Addendum to Iwai and Hoberman (2014)—Reassessment of developmental toxicity of pfhxa in mice. International Journal of Toxicology, 38(3), 183–191. https://doi.org/10.1177/1091581819837904
- Wang, Y., Niu, J., Zhang, L., & Shi, J. (2014). Toxicity assessment of perfluorinated carboxylic acids (Pfcas) towards the rotifer Brachionus calyciflorus. Science of The Total Environment, 491–492, 266–270. https://doi.org/10.1016/j.scitotenv.2014.02.028.
- Ali, J. M., Roberts, S. M., Gordon, D. S., & Stuchal, L. D. (2019). Derivation of a chronic reference dose for perfluorohexane sulfonate (Pfhxs) for reproductive toxicity in mice. Regulatory Toxicology and Pharmacology, 108, 104452. https://doi.org/10.1016/j.yrtph.2019.104452
- Viberg, H., Lee, I., & Eriksson, P. (2013). Adult dose-dependent behavioral and cognitive disturbances after a single neonatal PFHxS dose. Toxicology, 304, 185–191. https://doi.org/10.1016/j.tox.2012.12.013
- Lee, I., & Viberg, H. (2013). A single neonatal exposure to perfluorohexane sulfonate (Pfhxs) affects the levels of important neuroproteins in the developing mouse brain. NeuroToxicology, 37, 190–196. https://doi.org/10.1016/j.neuro.2013.05.007
- Vogs , C., Johanson, G., Näslund, M., Wulff, S., Sjödin, M., Hellstrandh, M., Lindberg, J., & Wincent, E. (2019). Toxicokinetics of perfluorinated alkyl acids influences their toxic potency in the zebrafish embryo(danio rerio). Environmental Science & Technology, 53(7), 3898–3907. https://doi.org/10.1021/acs.est.8b07188
- Chang, S., Butenhoff, J. L., Parker, G. A., Coder, P. S., Zitzow, J. D., Krisko, R. M., Bjork, J. A., Wallace, K. B., & Seed, J. G. (2018). Reproductive and developmental toxicity of potassium perfluorohexanesulfonate in CD-1 mice. Reproductive Toxicology, 78, 150–168. https://doi.org/10.1016/j.reprotox.2018.04.007
- Butenhoff, J. L., Chang, S.-C., Ehresman, D. J., & York, R. G. (2009). Evaluation of potential reproductive and developmental toxicity of potassium perfluorohexanesulfonate in Sprague Dawley rats. Reproductive Toxicology, 27(3), 331–341. https://doi.org/10.1016/j.reprotox.2009.01.004
- Cassone, C. G., Vongphachan, V., Chiu, S., Williams, K. L., Letcher, R. J., Pelletier, E., Crump, D., & Kennedy, S. W. (2012). In ovo effects of perfluorohexane sulfonate and perfluorohexanoate on pipping success, development, mrna expression, and thyroid hormone levels in chicken embryos. Toxicological Sciences, 127(1), 216–224. https://doi.org/10.1093/toxsci/kfs072
- Kim, S.-J., Heo, S.-H., Lee, D.-S., Hwang, I. G., Lee, Y.-B., & Cho, H.-Y. (2016). Gender differences in pharmacokinetics and tissue distribution of 3 perfluoroalkyl and polyfluoroalkyl substances in rats. Food and Chemical Toxicology, 97, 243–255. https://doi.org/10.1016/j.fct.2016.09.017
- Cassone, C. G., Taylor, J. J., O’Brien, J. M., Williams, A., Yauk, C. L., Crump, D., & Kennedy, S. W. (2012). Transcriptional profiles in the cerebral hemisphere of chicken embryos following in ovo perfluorohexane sulfonate exposure. Toxicological Sciences, 129(2), 380–391. https://doi.org/10.1093/toxsci/kfs219
- Gordon, S. C. (2011). Toxicological evaluation of ammonium 4,8-dioxa-3H-perfluorononanoate, a new emulsifier to replace ammonium perfluorooctanoate in fluoropolymer manufacturing. Regulatory Toxicology and Pharmacology, 59(1), 64–80. https://doi.org/10.1016/j.yrtph.2010.09.008
- Bogdanska, J., Sundström, M., Bergström, U., Borg, D., Abedi-Valugerdi, M., Bergman, Å., DePierre, J., & Nobel, S. (2014). Tissue distribution of 35S-labelled perfluorobutanesulfonic acid in adult mice following dietary exposure for 1-5days. Chemosphere, 98, 28–36. https://doi.org/10.1016/j.chemosphere.2013.09.062
- Chen, F., Wei, C., Chen, Q., Zhang, J., Wang, L., Zhou, Z., Chen, M., & Liang, Y. (2018). Internal concentrations of perfluorobutane sulfonate (PFBS) comparable to those of perfluorooctane sulfonate (PFOS) induce reproductive toxicity in Caenorhabditis elegans. Ecotoxicology and Environmental Safety, 158, 223–229. https://doi.org/10.1016/j.ecoenv.2018.04.032
- Chen, L., Lam, J. C. W., Hu, C., Tsui, M. M. P., Lam, P. K. S., & Zhou, B. (2019). Perfluorobutanesulfonate exposure skews sex ratio in fish and transgenerationally impairs reproduction. Environmental Science and Technology, 53(14), 8389–8397. https://doi.org/10.1021/acs.est.9b01711
- Chen, L., Tsui, M. M. P., Hu, C., Wan, T., Au, D. W. T., Lam, J. C. W., Lam, P. K. S., & Zhou, B. (2019). Parental Exposure to Perfluorobutanesulfonate Impairs Offspring Development through Inheritance of Paternal Methylome. Environmental Science and Technology, 53(20), 12018–12025. https://doi.org/10.1021/acs.est.9b03865
- Chen, L., Tsui, M. M. P., Shi, Q., Hu, C., Wang, Q., Zhou, B., Lam, P. K. S., & Lam, J. C. W. (2018). Accumulation of perfluorobutane sulfonate (PFBS) and impairment of visual function in the eyes of marine medaka after a life-cycle exposure. Aquatic Toxicology, 201, 1–10. https://doi.org/10.1016/j.aquatox.2018.05.018
- Hagenaars, A., Vergauwen, L., De Coen, W., & Knapen, D. (2011). Structure-activity relationship assessment of four perfluorinated chemicals using a prolonged zebrafish early life stage test. Chemosphere, 82(5), 764–772. https://doi.org/10.1016/j.chemosphere.2010.10.076
- Lou, Q. Q., Zhang, Y. F., Zhou, Z., Shi, Y. L., Ge, Y. N., Ren, D. K., Xu, H. M., Zhao, Y. X., Wei, W. J., & Qin, Z. F. (2013). Effects of perfluorooctanesulfonate and perfluorobutanesulfonate on the growth and sexual development of Xenopus laevis. Ecotoxicology, 22(7), 1133–1144. https://doi.org/10.1007/s10646-013-1100-y
- Marziali, L., Rosignoli, F., Valsecchi, S., Polesello, S., & Stefani, F. (2019). Effects of Perfluoralkyl Substances on a Multigenerational Scale: A Case Study with Chironomus riparius (Diptera, Chironomidae). Environmental Toxicology and Chemistry, 38(5), 988–999. https://doi.org/10.1002/etc.4392
- Sant, K. E., Venezia, O. L., Sinno, P. P., & Timme-Laragy, A. R. (2019). Perfluorobutanesulfonic acid disrupts pancreatic organogenesis and regulation of lipid metabolism in the Zebrafish, Danio rerio. Toxicological Sciences, 167(1), 157–171. https://doi.org/10.1093/toxsci/kfy237
- Domínguez, A., Salazar, Z., Betancourt, M., Ducolomb, Y., Casas, E., Fernández, F., Bahena, I., Salomón, A., Teteltitla, M., Martínez, R., Chaparro, A., Cuapio, P., Salazar-López, C., & Bonilla, E. (2019). Effect of perfluorodecanoic acid on pig oocyte viability, intracellular calcium levels and gap junction intercellular communication during oocyte maturation in vitro. Toxicology in Vitro, 58(April), 224–229. https://doi.org/10.1016/j.tiv.2019.03.041
- Berntsen, H. F., Bjørklund, C. G., Audinot, J. N., Hofer, T., Verhaegen, S., Lentzen, E., Gutleb, A. C., & Ropstad, E. (2017). Time-dependent effects of perfluorinated compounds on viability in cerebellar granule neurons: Dependence on carbon chain length and functional group attached. NeuroToxicology, 63, 70–83. https://doi.org/10.1016/j.neuro.2017.09.005
- Jo, A., Ji, K., & Choi, K. (2014). Endocrine disruption effects of long-term exposure to perfluorodecanoic acid (PFDA) and perfluorotridecanoic acid (PFTrDA) in zebrafish (Danio rerio) and related mechanisms. Chemosphere, 108, 360–366. https://doi.org/10.1016/j.chemosphere.2014.01.080
- Johansson, N., Fredriksson, A., & Eriksson, P. (2008). Neonatal exposure to perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) causes neurobehavioural defects in adult mice. NeuroToxicology, 29(1), 160–169. https://doi.org/10.1016/j.neuro.2007.10.008
- Vanden Heuvel, J. P., Kuslikis, B. I., & Peterson, R. E. (1992). Covalent binding of perfluorinated fatty acids to proteins in the plasma, liver and testes of rats. Chemico-Biological Interactions, 82(3), 317–328. https://doi.org/10.1016/0009-2797(92)90003-4
- Vanden Heuvel, J. P., Kuslikis, B. I., Van Rafelghem, M. J., & Peterson, R. E. (1991). Disposition of perfluorodecanoic acid in male and female rats. Toxicology and Applied Pharmacology, 107(3), 450–459. https://doi.org/10.1016/0041-008X(91)90308-2
- Bookstaff, R. C., Moore, R. W., Ingall, G. B., & Peterson, R. E. (1990). Androgenic deficiency in male rats treated with perfluorodecanoic acid. Toxicology and Applied Pharmacology, 104(2), 322–333. https://doi.org/10.1016/0041-008X(90)90306-F
- Harris, M. W., Uraih, L. C., & Birnbaum, L. S. (1989). Acute toxicity of perfluorodecanoic acid in C57BL/6 mice differs from 2,3,7,8-tetrachlorodibenzo-p-dioxin. Toxicological Sciences, 13(4), 723–736. https://doi.org/10.1093/toxsci/13.4.723
- Harris, M. W., & Birnbaum, L. S. (1989). Developmental toxicity of perfluorodecanoic acid in C57BL/6N mice. Toxicological Sciences, 12(3), 442–448. https://doi.org/10.1093/toxsci/12.3.442
- Gutshall, D. M., Pilcher, G. D., & Langley, A. E. (1989). Mechanism of the serum thyroid hormone lowering effect of perfluoro-n-decanoic acid (Pfda) in rats. Journal of Toxicology and Environmental Health, 28(1), 53–65. https://doi.org/10.1080/15287398909531328
- Van Rafelghem, M. J., Mattie, D. R., Bruner, R. H., & Andersen, M. E. (1987). Pathological and hepatic ultrastructural effects of a single dose of perfluoro-n-decanoic acid in the rat, hamster, mouse, and Guinea pig. Toxicological Sciences, 9(3), 522–540. https://doi.org/10.1093/toxsci/9.3.522
- Van Rafelghem, M. J., Inhorn, S. L., & Peterson, R. E. (1987). Effects of perfluorodecanoic acid on thyroid status in rats. Toxicology and Applied Pharmacology, 87(3), 430–439. https://doi.org/10.1016/0041-008X(87)90248-1
- Langley, A. E., & Pilcher, G. D. (1985). Thyroid, bradycardic and hypothermic effects of perfluoro-n-decanoic acid in rats. Journal of Toxicology and Environmental Health, 15(3–4), 485–491. https://doi.org/10.1080/15287398509530675
- Boujrad, N., Vidic, B., Gazouli, M., Culty, M., & Papadopoulos, V. (2000). The peroxisome proliferator perfluorodecanoic acid inhibits the peripheral-type benzodiazepine receptor (PBR) expression and hormone-stimulated mitochondrial cholesterol transport and steroid formation in Leydig cells. Endocrinology, 141(9), 3137–3148. https://doi.org/10.1210/endo.141.9.7678
- Benninghoff, A. D., Orner, G. A., Buchner, C. H., Hendricks, J. D., Duffy, A. M., & Williams, D. E. (2012). Promotion of hepatocarcinogenesis by perfluoroalkyl acids in rainbow trout. Toxicological sciences : an official journal of the Society of Toxicology, 125(1), 69–78. https://doi.org/10.1093/toxsci/kfr267
- Benninghoff, A. D., Bisson, W. H., Koch, D. C., Ehresman, D. J., Kolluri, S. K., & Williams, D. E. (2011). Estrogen-like activity of perfluoroalkyl acids in vivo and interaction with human and rainbow trout estrogen receptors in vitro. Toxicological sciences : an official journal of the Society of Toxicology, 120(1), 42–58. https://doi.org/10.1093/toxsci/kfq379
- Ishibashi, H., Yamauchi, R., Matsuoka, M., Kim, J. W., Hirano, M., Yamaguchi, A., Tominaga, N., & Arizono, K. (2008). Fluorotelomer alcohols induce hepatic vitellogenin through activation of the estrogen receptor in male medaka (Oryzias latipes). Chemosphere, 71(10), 1853–1859. https://doi.org/10.1016/j.chemosphere.2008.01.065
The Universal Solvent
By Elaina Covey, Biochemistry & Molecular Biology ‘22
This is a digital painting I drew that was inspired by the importance of clean water on our planet. I painted this with my iPad Pro using the latest version of Procreate. The girl, who is the subject of this drawing, is meant to represent life on Earth. I stuck to a color palette consisting primarily of greens and blues to reflect nature and the planet. I was also inspired by a quote from American educator, Loren Eisely, who wrote in an essay titled “The Flow of the River” that “if there is magic on this planet, it is contained in water.” For this reason, I wanted to make a piece that evokes a feeling of magic and wonder. However, there is also a sense of danger. The girl, who is nearly drowning, serves to remind us that pollution in the form of oil runoffs, plastics, agricultural waste, and acidification threatens our oceans daily. Additionally, as carbon pollution increases and annual temperatures rise, sea levels are rising as well. The girl’s drowning may also serve to remind the viewer of the danger faced by many species who rely on our planet’s ice caps for survival. I hope this piece can inspire others to recognize the importance of protecting Earth’s amazing biodiversity.
Varying Efficacy and Safety Among Food Allergy Immunotherapy Methods
By Karishma Sira, Biological Sciences ‘21
Author’s Note: This review was originally written for my UWP104F class in Winter Quarter 2021. While environmental allergies are well known to the public, many people are unaware of the social, mental, financial, and most importantly, physical costs of food allergies. I highly benefited from getting treated for food allergies through immunotherapy, so I want to make these methods more known. I want to raise awareness on the available non-avoidant treatments catered to food allergy sufferers and inform readers that these methods are important developments happening in the world of food allergy immunotherapy. This article will also explain the basic mechanisms of immunotherapy, the differences between each delivery method, the relative effectiveness of these methods, and the risks and benefits of each method. These factors should all be considered when recommending a specific method to an allergic individual.
Food allergies are becoming an increasingly common global health crisis. The various consequences of living with food allergies reduces the quality of life for those affected [1]. Aside from the immediate dangers of severe allergic reactions, there is a significant amount of social restrictions and anxiety involved. Dealing with food allergies costs American individuals and families 25 billion dollars annually [2]. Avoidance diets are the most common way to treat food allergies, but they are statistically unsustainable: 75% of peanut-allergic children get accidentally exposed to peanuts by the time they are 5 years old [1]. As a result, allergy immunotherapy is an important developing preventative treatment that can allow individuals to consume allergens to improve quality of life.
There are three main emerging treatments: oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT). All three use different delivery methods to introduce the patient to allergens to achieve desensitization. The different delivery methods may contribute to the different levels of success observed between them.
The guiding principle of food allergy immunotherapy, regardless of delivery method, is to induce a state of prolonged desensitization–defined as an increase in tolerance threshold–to an allergen [3]. This may be achieved by maintaining consumption of allergen over time through doses tailored to the patient’s observed tolerance threshold. Tolerance thresholds are determined with food challenges, where the patient consumes allergens until they experience notable allergic symptoms [4]. Desensitization may be gradually achieved through increases in dosage [3, 4]. Allergen doses slowly increase over time as the patient’s tolerance increases. Administering the allergen this way is thought to familiarize the body with it so that the immune response to the allergen gradually becomes less severe over time [5].
Generally, the immune response to allergens is mediated by allergy-specific antibodies called Immunoglobulin E (IgE). Once a food allergen has been ingested and detected by the immune system, IgE activates immune cells that cause inflammation and other allergy symptoms. Immunotherapy attempts to change the immune response so that allergens stimulate non-allergy specific antibodies like Immunoglobulin G (IgG) [5]. IgG antibodies produce a normal immune response to foreign bodies like infections and viruses. Training the body to respond with IgG prevents the allergic response, eliminating adverse allergic symptoms.
Immunotherapy aims to create a state of long term desensitization known as sustained unresponsiveness (SU). By achieving SU, patients are more likely to retain tolerance even after they stop taking the regular, repeated doses of allergen. Patients with SU can often freely be in the presence of their allergens or even consume them [3, 4]. SU is not considered a “cure” of allergies. Immunotherapy simply aims to change the Immunoglobulin E-mediated allergic response to a less drastic response that has little to no effect on quality of life [1]. SU is less commonly achieved than desensitization across all delivery methods, with only a small subset of patients reaching SU after years of therapy [6]. Nonetheless, SU remains the ideal end goal for all patients [3].
Delivery Methods
Across all studies cited in this literature review, delivery methods vary in efficacy depending on the food allergen being treated. Discussing the efficacy of each method for individual food allergens would thus require extensive examination and comparison of many individual studies. This level of specificity is not necessary to explain or compare the efficacies of the three immunotherapies. The duration and safety of each treatment seems to widely vary based on the particular allergic response, tolerance threshold, and specific allergens of an individual. Despite these differences, however, much of the research yields consistent results in the overall relative efficacy of each method. As such, this review will describe a general consensus about the effectiveness of each delivery method across many studies.
Delivery Method #1 – Oral Immunotherapy
The first food allergy immunotherapy delivery method, which has recently received Food and Drug Administration (FDA) approval for peanut allergen [7] is oral immunotherapy (OIT). In OIT, the patient ingests allergen protein often in powder form and mixed with other non-allergenic food [5].
OIT has yielded the most promising clinical results out of all immunotherapy delivery methods [5]. Most patients treated with OIT have reached desensitization, though SU is less commonly observed [3]. Adverse allergic reactions are reasonably likely to occur during OIT, though most reactions are mild. All reactions can be promptly addressed within a clinical or hospital setting. Despite this, individuals with severe and fast-acting allergic reactions (e.g. anaphylaxis) may still face risks to their physical well-being [3, 6]. As of now, only an OIT treatment, known as PalforziaⓇ, for peanut allergen has been approved by the FDA out of all potential immunotherapies. At this point in time, it has passed clinical trials and requires additional risk assessments, education, and patient counseling for use [7].
Adjuvant medications–used in combination with a treatment to enhance or modify its effects are being examined as additional safety measures to make OIT safer. Omalizumab is a monoclonal antibody, an antibody cloned from existing antibodies that can be taken as medicine to assist immune functions. Omalizumab selectively binds to IgE, which occupies IgE enough to suppress the allergic response [8]. Omalizumab appears to have no bearing on the effectiveness of the desensitization process [3]. However, it has been shown to speed up the process and decrease incidence of adverse allergic reactions. For common allergens like milk and peanut, little to no adverse reactions were observed when Omalizumab was administered to subjects [8]. However, further research and clinical trials with larger sample sizes and a wider array of allergens must be conducted before Omalizumab can be universally used as a safety protocol for food allergy immunotherapy [8].
Delivery Method #2 – Sublingual Immunotherapy
The second delivery method is sublingual immunotherapy (SLIT). SLIT requires that liquid or dissolvable extracts of allergens be regularly administered under the tongue, held there for a time, and then swallowed [5]. Using this method, the allergen can be mainly taken into the body by way of antigen presenting cells in the sublingual mucosa found under the tongue. This route avoids enzymes encountered during gastric digestion that might change the structure of the allergen protein. This is useful in ensuring that the immune system becomes fully desensitized to the correct allergen [6].
One advantage of SLIT is its safety; adverse allergic reactions and anaphylaxis are not commonly observed [5, 6]. Additionally, using SLIT before OIT is highlighted as a potential benefit. Patients who experience adverse reactions with OIT generally are advised to use SLIT as a stepping stone treatment. This lets them build enough desensitization to make OIT a more viable option, as they experience less side effects [5].
Delivery Method #3 – Epicutaneous Immunotherapy
The third delivery method in food allergy immunotherapy is epicutaneous immunotherapy (EPIT). Immune cells in the skin called Langerhans cells help introduce the allergen to the body when dermal patches are applied to the skin [5, 9]. Patches are kept on for increasingly longer durations and replaced as instructed by a physician until the patient is mostly unresponsive to the allergen. At this point, patches must still be worn to maintain results, but need only be replaced every 24 hours [2].
Using this route to absorb allergens successfully prevents entry to vasculature, which is thought to limit severe systemic allergic reactions and only results in mild, cutaneous reactions [1, 9]. Similar to SLIT, this makes EPIT’s safety profile better than OIT’s. Additionally, EPIT does not place restrictions on the patient’s lifestyle and does not require close clinical observation like OIT or SLIT [2].
Comparing Delivery Methods
As mentioned earlier, OIT is largely considered the most effective of the three immunotherapies described. Most patients are successfully desensitized and SU, though still infrequent, it occurs more often than other methods [3, 5].
SLIT has shown modest levels of desensitization, but is overall considered less effective than OIT, showing less immunologic changes over time [6]. It does not appear to confer high levels of SU [5]. It is unknown whether this is attributed to the fact that most patients appear to struggle with completing the recommended duration of treatment [9].
EPIT also demonstrates levels of desensitization comparable to SLIT, with 28-50% of patients showing tolerance to their allergen on average [1, 2]. SU has not been well documented in either EPIT or SLIT [1], which seems to be the main reason why they do not have FDA approval [2].
Conclusions
Preventative food allergy immunotherapy has been a developing area of study due to a global increase in food allergy incidence [5]. Three prominent immunotherapy delivery methods have emerged with differing efficacies and safety profiles.
OIT is widely considered the most clinically efficient and promising delivery method, since it consistently produces desensitization [5]. SLIT shows less consistent desensitization [6] and maintaining treatment is difficult for patients. EPIT shows similar results to SLIT [9]. While SU is not commonly achieved, it is more common in OIT [1, 3], which may explain why the only FDA-approved food allergy immunotherapy is OIT for peanut allergen [7].
The safety and convenience of each method may also affect patient choice. OIT may be the most effective and quick-acting, but it also runs the largest risk of adverse reactions, which warrants close clinical attention during treatment [3, 6]. In contrast, SLIT does not seem to cause many adverse reactions and is encouraged as a stepping stone treatment for patients that would like to move on to OIT once more tolerance to their allergen is built up. This practice seems to make OIT much safer [5] along with the use of medications like Omalizulab [8]. EPIT is also safer than OIT but has the added advantage of being a convenient and low maintenance treatment [5, 9]. At maintenance, dermal patches used for EPIT only need to be replaced every 24 hours, no clinical observation is required, and there are no restrictions placed on the patient’s lifestyle [2].
As allergies become more common across the globe, more children struggle to adhere to avoidance diets and become vulnerable to accidental exposure to allergens [1]. Immunotherapy methods have developed in the hopes of increasing the quality of life of these food allergic individuals [1]. Future research may be able to improve on the observed effects and safety of immunotherapy. Ultimately, any progress will be able to help food allergy sufferers improve their quality of life.
References:
- Costa, C., Coimbra, A., Vítor, A., Aguiar, R., Ferreira, A. L., & Todo-Bom, A. (2020). Food allergy – From food avoidance to active treatment. Scandinavian journal of immunology, 91(1), e12824. doi:10.1111/sji.12824
- Kim, E. H., & Burks, A. W. (2020). Food allergy immunotherapy: Oral immunotherapy and epicutaneous immunotherapy. Allergy, 75(6), 1337–1346. doi:10.1111/all.14220
- Wood R. A. (2017). Oral Immunotherapy for Food Allergy. Journal of investigational allergology & clinical immunology, 27(3), 151–159. doi:10.18
- Marcucci, F., Isidori, C., Argentiero, A., Neglia, C., & Esposito, S. (2020). Therapeutic perspectives in food allergy. Journal of translational medicine, 18(1), 302. doi:10.1186/s12967-020-02466-x
- Burks, A. W., Sampson, H. A., Plaut, M., Lack, G., & Akdis, C. A. (2018). Treatment for food allergy. The Journal of allergy and clinical immunology, 141(1), 1–9. doi:10.1016/j.jaci.2017.11.004
- Scurlock A. M. (2018). Oral and Sublingual Immunotherapy for Treatment of IgE-Mediated Food Allergy. Clinical reviews in allergy & immunology, 55(2), 139–152. doi:10.1007/s12016-018-8677-0
- Caccomo, S. (2021). FDA approves first drug for treatment of peanut allergy for children. U.S. Food and Drug Administration. <https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treatment-peanut-allergy-children>.
- Dantzer, J. A., & Wood, R. A. (2018). The use of omalizumab in allergen immunotherapy. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 48(3), 232–240. doi:10.1111/cea.13084
- Reisacher, W. R., & Davison, W. (2017). Immunotherapy for food allergy. Current opinion in otolaryngology & head and neck surgery, 25(3), 235–241. doi:10.1097/MOO.0000000000000353
Non-Invasive Brain Stimulation Therapies as Therapeutics for Post-Stroke Patients
By Priyanka Basu, Neurobiology, Physiology & Behavior ‘22
Author’s Note: I wrote this review article during my time in UWP102B this past quarter, though my inspiration in digging deeper into this topic came from my personal experience with my uncle who had recently incurred a stroke to his brain leading him to face its detrimental effects. I realized I wanted to investigate the possible solutions there were for him and others, allowing me to consequently further my knowledge about this field of study. I’d love for readers to understand the complexity and dynamics that non-invasive brain stimulation therapies have on post-stroke patients, and its beneficial effects when used in conjunction with other therapies. Though studies are in their preliminary phases and there are quite a bit of unknowns, it is still important to keep in mind the innumerable therapeutics being created that target patient populations experiencing a certain extent of brain damage- their results are absolutely phenomenal.
Abstract:
Non-invasive brain stimulation therapies have become an overwhelmingly dominant innovation of biotechnology that has proven to be greatly effective for treating post-cerebral damage. Stimulation therapies use magnetic fields that can induce electric fields in the brain by administering intense electric currents that pulse through neural circuits. Although several stimulation therapies exist, the therapies discussed in this review include the most widely used therapeutic technologies: transcranial magnetic stimulation (TMS), repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), and theta-burst stimulation (TBS). Post-stroke patients often experience significant impairments to their sensorimotor systems that may include the inability to make arm or hand movements, while other impairments include memory or behavioral incapacities. Stimulatory therapies have been shown to allow for certain neuronal excitability that can improve the impairments seen in these patients unlike alternative standardized procedures. Although the individual efficacies of stimulation therapies have shown viable outcomes, current research dives into how the use of stimulation therapies in conjunction with secondary therapeutics can have synergistic effects.
Introduction:
Basic stimulation therapies were first put to clinical use in 1985 to investigate the workings of the human corticospinal system [1]. The magnetic field that is produced by stimulation is capable of penetrating through the scalp and neural tissue, easily activating neurons in the cortex and strengthening the electrical field of the brain [1]. By inducing depolarizing currents and action potentials in certain regions of the brain, patients with damaged areas of the cerebral cortex found great relief as they regained a degree of normal functionality in their motor, behavioral, or cognitive abilities [1].
In recent years, stroke has become the second leading cause of death in the United States [2]. Neurologically speaking, stroke can interrupt blood flow in regions of the brain, such as the motor cortex, weakening overall neurological function throughout the body [2]. Stimulatory therapies are used in these cases to successfully activate neurons which jumpstarts their firing capabilities and rewires the body’s normal functionality [1]. Although certain reperfusion therapies using thrombolysis have been seen to treat certain ischemic (i.e. hemorrhaged) tissue in stroke patients by removing deadly clots in blood vessels, these therapeutics are often starkly inaccessible to the general population because of their price tag and scarcity [2]. Oftentimes, even standard pharmacological drugs prove ineffective [2]. By way of heavy experimentation, scientists have discovered that the brain can simply reconstruct itself through a method called, “cortical plasticity,” allowing for neural connections to be modified back to their normal firing pattern [3]. By understanding this innate and adaptive tool that the brain possesses, researchers invented the method of stimulatory therapies to essentially boost our own neural hardware [2].
Over the years, by investigating how these therapies and their mechanisms can work in conjunction with other therapeutics on post-stroke patients, an in-depth understanding of further possible advantageous therapies can be made.
Mechanism of Non-Invasive Neural Stimulation
Most current noninvasive brain stimulation therapies use similar methodologies involving the induction of magnetic fields or electrical currents along cerebral cortical regions of the skull and brain to induce rapid excitation of neurons [4]. Some of the most common noninvasive brain stimulation (NIBS) techniques currently used are transcranial magnetic stimulation (TMS), repetitive transcranial magnetic stimulation (rTMS), transcranial direct current stimulation (tDCS), and theta-burst stimulation (TBS) [4]. Our brains reorganize innately after stroke or cerebral damage through mechanisms of cortical plasticity [3]. However, non-invasive stimulation therapies can stimulate cortical plasticity by quickly modulating neural connections through electrical activation for efficient neuronal and/or motor recovery after the incident [3]. According to Takeuchi et al., TMS and other similar therapies stimulate the cortex through the scalp and the skull. This method positions a coiled wire over the scalp to generate a local magnetic field [4]. As these magnetic fields are pulsed and begin to enter the brain, they establish an electrical current that stimulates cortical neurons which induces a neuronal depolarization (i.e. excitation) [4]. rTMS involves a similar mechanism as TMS, but it has a greater rate of repetition of the ejected magnetic stimulation inducing a higher frequency current [5]. Meanwhile, TBS therapy is a modification of rTMS. While TBS has a similar degree of frequency to rTMS, TBS involves larger bursts of magnetic stimulation rather than small, frequent action [6].
When understanding the degree that noninvasive brain stimulation works on cortical neural plasticity, it is best to see its functionality in the motor cortex—one of the most easily damaged regions of the brain in stroke patients [4]. Neuronally, NIBS can excite the damaged hemisphere allowing for an increase in activity of the opposite or ‘ipsilesional’ motor cortex [4]. This excitement is highly inducible and is required for proper motor learning and functioning in normal human behavior [7,8]. In addition, these therapeutics may also induce certain metabolic changes that stimulate our innate neural plastic network for successful post-stroke motor recovery [4]. Over time, and with continuous electric stimulation therapy, long-term potentiation of our neural hardware can lead to swift recovery of the affected hemisphere [3]. By this method of magnetic stimulation on damaged cortical regions of the brain, post-stroke patients can recover faster than ever before.
Excitability of Motor and Behavioral Neural Networks
Ultimately, NIBS treatments induce excitability of motor and behavioral neural networks that allow for the atrophy of affected cerebral regions and increase neural plasticity in the region [5]. In a study led by Delvaux et al., TMS therapies were used to excite changes in the reorganization of motor cortical areas of post-stroke patients [9]. Scientists investigated a group of 31 patients that experienced an ischemic stroke in their middle cerebral artery which led to severe hand palsy [9]. The patients were clinically assessed with the Medical Research Council, the National Institutes of Health stroke scales, and Barthel Index on certain dates of experimentation after stroke [9]. From the data collected, when damaged regions were measured by electrical motor-evoked potential (MEP) amplitudes, the areas were initially statistically smaller than the unaffected areas, thus indicating a lesser degree of motor activation resulting from the effects of certain damaged regions of the brain [9]. After the affected regions were treated with focal transcranial magnetic stimulation (fTMS), a specific type of TMS therapy, the stimulation ultimately induced excitability of affected motor regions as well as unaffected motor regions due to the inducible nature of connected regions in the brain [9]. This study evaluates a TMS technique involving MEP amplitude measurements and FDI motor maps unique to most other stimulatory therapies, including rTMS, tDCS, and others, helping to physiologically understand the impacts of neurological damage in the brain. Although the study hosted a relatively small sample size of twenty participants, it can be considered sufficient as per the extremity of the experimental design and scarcity of possible participants. The study participants, ranging between 45 and 80 years old, were tested for any underlying neurological disorders to reduce confounding factors. By testing these participants using a standardized scaling method and MEP potentials, the study qualified as a well-regulated results-directive for a conclusive study despite a relatively small sample size.
A similar study conducted by Boggio et al. further investigated the effects of NIBS on motor and behavioral neural networks by using variant-charged (anodal (+) and cathodal (-)) current stimulations on stroke patients and then identifying enhanced results. The investigation studied a specific brain stimulatory therapeutic (tDCS) on its excitability and potential benefits on post-stroke patients [7]. Investigators were able to test the motor performance and improvements in stroke patients using two experiments [7]. Experiment 1 was conducted during four weekly sessions using sham (controlled magnetic stimulation), anodal (increased magnetic stimulation), and cathodal (decreased magnetic stimulation) transcranial direct current stimulation (tDCS) therapies [7]. In Experiment 2, five daily sessions of only cathodal tDCS treatments were investigated on affected brain regions [7]. The effects were reported following the procedure and blindly evaluated using the Jebson-Taylor Hand Function Test, a standardized test to measure gross motor hand function [7]. Between the two experiments, the most significant motor and behavioral improvements were found using the three stimulations in Experiment 1 [7]. However, when stimulations were compared individually, viable motor functional improvement was still evident with either cathodal or anodal tDCS on unaffected and affected hemispheres respectively when compared to the sham tDCS therapy [7]. Using daily sessions instead of weekly was found to be more beneficial in terms of lasting treatment results [7]. Investigators were able to conclude that their findings show strong support in relation to other tDCS research on motor function improvement in stroke patients [7]. tDCS is considered safe, representative, and inexpensive allowing for the possibility of further research on the technique with a wider range of patients. The study could have included additional evaluations of the different motor capabilities rather than just focusing on the hand itself to allow for variation, additional variables, and details that could supply the research rather than simply validating the technique. Both experiments analyzed above resulted in statistically significant results and represented the excitable capabilities of stimulatory therapies currently used for post-stroke patients.
Effectivity of Alternative Neural Therapeutics in Conjunction with NIBS Therapies
Although standard NIBS therapies have been shown to provide impressive solutions for post-stroke patients, there have been few studies understanding the prospects of using NIBS in conjunction with other therapies for these patients. Aphasia, a rapid decline of the ability to acknowledge or express speech, is a common neurological disorder often seen in post-stroke patients as a result of damage to speech and language control centers of the brain [10]. A number of therapeutics not only search for solutions to certain post-stroke motor dysfunctionalities, but also the behavioral dysfunctions of stroke including aphasias. For several years, previous studies have investigated the use of intonation-based intervention (melodic intonation therapy (MIT)), on severe non-fluent aphasia patients showing immense benefits [10]. A study conducted by Vines et al. (2011) expanded on these findings and implemented this therapy of MIT alongside an additional brain stimulatory therapy of transcranial direct current stimulation (tDCS) to understand if there are augmented benefits of MIT in patients with non-fluent aphasia [10]. Six patients with moderate to severe non-fluent aphasia underwent three days of anodal-tDCS therapy with MIT and another three days with sham-tDCS therapy with MIT [10]. The two types of treatments were separated by one week and assigned randomly [10]. The study showed that compared to the effects of the sham-tDCS with MIT therapies, the anodal-tDCS with MIT led to statistically significant improvements in the patients’ fluency of speech [10]. The study was able to solidify that the brain can properly reorganize and heal damage to its language centers through combined therapies of anodal-tDCS and MIT thus revamping the neurological activity of non-fluent aphasia patients [10]. However, one important component that was lacking in this experiment was a large number of subjects for reliable results. With six patients in the study, scientists could have increased the number tested to allow for greater sufficiency and valid results. Although this study lacked in size, it did include a range of participant ages relieving confounding effects of age-related neurological differences.
An additional study important to the investigation of understanding the prospects of conjunctive stimulatory therapy was conducted in 2012 by Avenanti et al. The study sought to understand the possible benefits of combining non-invasive brain stimulation therapies (rTMS) with physical therapy. Many studies have investigated the effects of TMS alone on chronic stroke patients but few have investigated the combination of TMS with physical therapy. In a double-blind, randomized, experiment, Avenanti et al. (2012) investigated a group of 30 patients who were given either real or sham transcranial magnetic stimulations (rTMS) either before or after physical therapy (PT) [5]. The outcomes of this experiment were evaluated based on dexterity and force manipulations of motor control [5]. The results of the study found that overall, patients that were given real rTMS treatments developed statistically better behavioral and neurophysiological outcomes when used in conjunction with PT but were more greatly enhanced when stimulated before physical therapy in a sequential manner [5]. Improvements were detected in all conjunctive groups (real or sham/before or after PT), and even with PT alone in certain experimental groups [5]. Researchers were able to conclude that treating chronic stroke patients with motor disabilities with rTMS before PT provided optimal results of motor excitability, though its conjunctive outcome was effective as well [5]. With statistically significant results, the study indicates valid conjunctive benefits of both PT and rTMS therapy for the patients evaluated [5]. Regarding the reliability of this study, each method was properly implemented for results to be sustained allowing for proper controls in sham trials [5].
Conjunctive therapies offer new insight into possible avenues for advantageous treatments for post-stroke patients rather than when used alone. With new investigations in this field of study, unknown outlets are slowly being uncovered, allowing for better solutions to cerebral and ischemic damage.
Conclusion:
Non-invasive brain stimulation (NIBS) therapies are a well-refined and successful therapeutic for post-stroke patients. Although much of the mainstream solutions to damaged cerebral regions are NIBS therapies, current research is still searching to identify qualifying conjunctive therapies with NIBS to ameliorate treatments. Standard stimulatory procedures use measurable magnetic or electric currents to depolarize or excite regions of the brain to stimulate neurons for proper activity. By doing so, our innate system of neural plasticity works with this stimulation to enhance the recovery of damaged cerebral regions. In recent years, scientists have taken a step further and combined stimulatory therapies with additional stroke therapy to further enhance results. Although early research processes have begun, more studies and trials are necessary to provide for sufficient data to strongly confirm their efficacies, even when promising results have already been found. Several studies lack the number of participating patients, data, and resources needed to successfully prove these conjunctive therapies. Further understanding of these treatments through repeated trials, larger sample sizes, and statistically significant results may lead to a better understanding in the future of possible effective conjunctive treatments for post-stroke patients.
References:
- Santos MD dos, Cavenaghi VB, Mac-Kay APMG, Serafim V, Venturi A, Truong DQ, Huang Y, Boggio PS, Fregni F, Simis M. 2017. Non-invasive brain stimulation and computational models in post-stroke aphasic patients: single session of transcranial magnetic stimulation and transcranial direct current stimulation. A randomized clinical trial. Sao Paulo Medical Journal. 135(5): 475–480.
- Kubis N. Non-Invasive Brain Stimulation to Enhance Post-Stroke Recovery. 2016. Front Neural Circuits. 10:56.
- Chen R., Cohen L. G., Hallett M. 2002. Nervous system reorganization following injury. Neuroscience 111, 761–773.
- Takeuchi N, Izumi S. 2012. Noninvasive brain stimulation for motor recovery after stroke: mechanisms and future views. Stroke Res Treat. 584727.
- Avenanti A., Coccia M., Ladavas E., Provinciali L., Ceravolo M. G. 2012. Low-frequency rTMS promotes use-dependent motor plasticity in chronic stroke: a randomized trial. Neurology 78, 256–264.
- van Lieshout ECC, Visser-Meily JMA, Neggers SFW, van der Worp HB, Dijkhuizen RM. 2017. Brain stimulation for arm recovery after stroke (B-STARS): protocol for a randomised controlled trial in subacute stroke patients. BMJ open. 7(8): e016566.
- Boggio P. S., Nunes A., Rigonatti S. P., Nitsche M. A., Pascual-Leone A., Fregni F. 2007. Repeated sessions of noninvasive brain DC stimulation is associated with motor function improvement in stroke patients. Restor Neurol Neurosci. 25, 123–129.
- Bucur M, Papagno C. 2018. A systematic review of noninvasive brain stimulation for post-stroke depression. Journal of affective disorders. 238: 69–78.
- Delvaux V., Alagona G., Gérard P., De Pasqua V., Pennisi G., Maertens de Noordhout A. 2003. Post-stroke reorganization of hand motor area: a 1-year prospective follow-up with focal transcranial magnetic stimulation. Clin. Neurophysiol. 114, 1217–1225.
- Vines BW, Norton AC, Schlaug G. 2011. Non-invasive brain stimulation enhances the effects of melodic intonation therapy. Frontiers in psychology. 2:230.
Sox10 as a Focal Point for Understanding Schwann Cell Differentiation
By Carly Adamson, Neurobiology, Physiology & Behavior ‘21
Author’s Note: I wrote this literature review for a UWP 104E assignment for which we could pick any science topic that interested us. I chose neural crest cells (NCCs) because they are the research focus of Dr. Crystal Rogers’ developmental biology lab, which I intern for on campus, and have such diverse fates. When I wrote this piece, I had just started my internship, and I wanted to connect the lab’s research to my own interests in the peripheral nervous system. This review explains and connects five key discoveries within the history of NCC development research. My intention was to split my audience into both neurodevelopmental specialists and a broader group of biologists with little background in NCCs. I used the terminology necessary for this specialized analysis while also drawing main conclusions in simpler language. I relate to the reader with metaphorical and illustrative language, as I yearned for such explanations in my own exploration of this complex research topic.
Abstract
Schwann cell (SC) development through neural crest cell (NCC) migration and differentiation is a fascinating and important topic since these cells are critical for nervous system function. On the journey to becoming SCs, some Schwann cell precursors (SCPs) stay in their partially-differentiated state to guide other developing cells and to provide a ready supply of a variety of NCC derivatives whenever needed in development. There is a lot left to understand in this intricate process, including how the timeline of SCP development aligns with other neurodevelopmental processes. This research review focuses on key studies about the network of transcription factors, regulators, and enzymes that take multipotent cells from a central region to the final fate of SC maturity. This review also highlights Sox10, a key transcription factor, as a central point to ground the reader in all other discoveries surrounding SC differentiation.
Keywords: Schwann cells, Schwann cell precursors, Sox10, neural crest cells, neurodevelopment, glial growth factor
Introduction
Neural crest cells (NCCs) are the foundation for a variety of key structures, from pigment cells of the skin to neurons and glia of the periphery. NCCs are multipotent, meaning that they can continue to divide in an undifferentiated state as well as differentiate into a wide range of mature cell types. However, they are also the starting point for many pathologies in abnormal development, including digestive tract abnormalities, motor disabilities, and cancer [1]. These fascinating cells have long been shown to differentiate based on networks of environmental signals, as shown by extensive transplantation experiments [2]. All NCCs originate from a structure aptly named the neural crest (NC), which distinguishes vertebrates from other chordates [3]. There are many gene networks to pattern the differentiation, migration, and maintenance of pluripotency of these cells. NCCs must delaminate from the neural tube and migrate to their target tissues after a process known as epithelial-mesenchymal transition (EMT) to become diverse derivatives such as craniofacial bone, pigment, or neurons in the developing organism. Some NCCs even stay multipotent after migration to establish local stem cell populations [4]. NCCs were first described by Dr. Wilhelm His over 150 years ago, and so much about the cells’ diverse functions has been uncovered since then.
One of these diverse functions is the formation of Schwann cell precursors (SCPs). These NCC derivatives migrate along embryonic nerve fibers, supplying stem cells wherever needed in the embryo [5]. After a whirlwind of developmental signaling pathways and context-dependent regulation, mature Schwann cells (SCs) are created. SCs are a key player in the peripheral nervous system, providing insulation and structural support to nerves [6]. SCs create multilayered fatty structures called myelin sheaths that allow action potentials to quickly conduct along a nerve fiber. While a developing embryo must regulate many cell proliferation and differentiation processes at once, it is important to specifically balance SC myelination and differentiation to efficiently develop peripheral nerves that can relay information to their neighbors and listen to external signals. A failure to balance these processes can lead to motor and sensory disabilities in an individual. In addition, the number of SCs that proliferate must match the number of axons in a one-to-one relationship to properly sort cells for subsequent myelination [1]. This balance requires a hefty molecular team, each with key roles in guiding SCs to maturity.
A main player in SC development is Sox10, a protein that induces NCCs to differentiate into components of the peripheral nervous system. Sox10 is a transcription factor, meaning that it binds a specific DNA sequence to regulate the expression of other genes. Sox10 has been linked to a multitude of developmental processes, including three activities relevant to this review: the formation of the neural crest itself, the formation of the peripheral nervous system, and the complete differentiation process of SCs. Without the expression of the Sox10 gene, no glial cells can form in vivo or in vitro [6]. Since Sox10 plays such key roles in multiple stages of vertebrate development, its expression must be tightly regulated. In order to understand the path from multipotent NCCs to fully-developed SCs that keep the organism alive, one must dive into the complicated web of Sox10 control.
Identification of potential SC development factors
The significance of early work in SC development studies can be sorted into two categories: 1) setting the foundation for NCC isolation techniques and 2) identifying genes for further inquiry into their potential roles in SC development. A publication by Buchstaller et al. in the Journal of Neuroscience describes the genetic methods of expressing fluorescent proteins in mice to identify and isolate NCCs and developing SCs. It is important to obtain pure populations of NCCs to study their development and differentiation, as a clean starting point gives the most accurate results once specific induction factors are applied. These broad methods, along with the genetic protocols of RNA amplification and in situ hybridization, allowed later researchers to study many different NCC lineages. A notable candidate selected from this study is Oct6, a transcription factor that will be further discussed below for its role in SC development [7]. The work of Buchstaller et al. provided the foundation for further investigations into the roles of individual transcription factors and signaling proteins in SC differentiation.
Neuregulin-1/ErbB signaling
A key discovery earlier in neural crest experimentation was a particular environmental factor, glial growth factor (GGF), also known as neuregulin-1, that prevents rat NCCs from differentiating into neuronal cells and instructs them to instead differentiate into glial components, such as SCs. This environmental factor works to inhibit Mash1, a very early and essential marker for neuronal differentiation. By blocking Mash1, neuregulin-1 prohibits developing cells from ever starting down the path to neuronal maturity, suppressing the fate of neurons entirely. This result, along with rigorous experiments designed to replicate this finding, identified GGF as the first factor shown to both promote one NCC fate and suppress another [2]. This study changed the theory of SC differentiation by confirming neuregulin-1 as a key SC regulator and proposing the mechanism behind it.
Later research further investigated the role of neuregulin-1 in SC development by focusing on the protein’s interplay with Sox10. A 2020 study from Yang et al. found that the signaling pathway involving neuregulin-1 and its family of epidermal growth factor receptors, ErbB type, maintains expression of Sox10 in differentiating SCPs [6]. By uncoupling ErbB signaling from SC differentiation via two experimental groups, this study was able to show that the combination of ErbB2 and neuregulin are required to produce SC phenotypes and that neuregulin works by affecting Sox10 expression.
Oct6’s synergy with Sox10
Oct6 is a transcription factor that works synergistically with Sox10 to promote the myelination of SCs [6]. Jagalur et al. used cell culture and cloning methods in rat models to elucidate the role of Oct6 in connecting the regulation networks of the promyelinating SC, which has been paired with a neuron but lacks a complete myelin sheath, to the SC that actively ensheaths axons. The 2011 paper concluded through comparative genome studies that Sox10 proteins pair up to form structures called dimers and bind the Oct6 gene. This interaction creates a greater regulatory complex and allows developing SC populations to respond to environmental cues [8]. This study defines a key regulatory mechanism for timing the onset of SC myelination, which is highly important to neurodevelopment in an individual and acutely affects their prognosis. This understanding of Oct6 provides another piece to the puzzle of SC development: differentiating NCCs must be able to understand cues from pre-existing, mature cells.
Histone deacetylases modify multiple SC factors
Figure 1: Bottom left image shows that the inhibition of HDAC1/2 yields lower Pax3 expression in JoMa1 cells. Image credit: Jacob et al., doi:10.1523/jneurosci.5212-13.2014.
Histone deacetylases are transcriptional regulators that remove acetyl groups from DNA histones to condense chromatin and to decrease DNA interactions with transcription factors. These enzymes can also remove acetyl groups from transcription factors themselves to modulate their activity. These enzymatic activities tie into SC development as demonstrated by Jacob et al.’s discovery in 2014 on the functions of histone deacetylase 1 and 2 (HDAC1/2). This study explains that HDAC1/2 are necessary for the myelination and complete maturation of SCs. These enzymes can be placed into the web of protein interactions that together regulate SC differentiation and myelination. This study used a combination of mouse neural crest explants and colonies, which differentiate into glial components in the presence of neuregulin, from the NCC-derived lineage called JoMa1 to get a more complete picture of transcriptional regulation. Jacob et al. show that HDAC1/2 unwind the tightly-packed DNA of the Pax3 gene to facilitate the expression of Pax3, an important transcription factor that maintains Sox10 [9]. This study produced a major change in theory due to the recognition of HDAC1/2 as induction factors for peripheral glia, including SCs, through their control of lineage-specific transcription factors, like Sox10.
Hippo/YAP/TAZ signaling
Figure 2: Control numbers and myelination of Schwann cells contrasts sharply with TAZ/YAP double knockouts (dcKO) on the far right. Image credit: Deng et al., doi: 10.1038/ncomms15161.
Hippo signaling refers to a pathway that affects cell proliferation and a process of controlled cell death known as apoptosis.It is primarily moderated by three factors: Hippo, TAZ, and YAP. TAZ and YAP proteins activate cell cycle regulators to promote proliferation of SC. The two also work with Sox10 to direct differentiation regulators for myelination [3]. TAZ and YAP were found to regulate SC proliferation via the control of cell cycle regulators and regulate SC myelination through interactions with Sox10. The direct targets of these two proteins are still not fully understood, but immunolabeling results published from Deng et al. in 2017 revealed TAZ and YAP to be necessary for SC proliferation and myelin induction. Single knockouts , which disable the target gene from functioning in an organism, for TAZ or YAP in mice showed how these two proteins can compensate for one another’s expression to produce normal SC phenotypes if only one factor is present. In contrast, double knockout mice showed a dramatic reduction in mature SCs due to decreased Sox10 expression [1]. The research that led to understanding the interplay of TAZ and YAP in this signaling network is key to SC developmental theory because the prognosis of mice without these genes is so bleak. Individuals without the proper number of mature SCs are not viable for long after birth due to severe motor and sensory deficits. These unfortunate phenotypes show the importance of TAZ and YAP in SC development as well as the importance of SCs to vertebrate life.
Further neuregulin-1/ErbB signaling analysis
Research on the neuregulin-1/ErbB signaling mechanism is key to understanding SC differentiation because this signaling makes important decisions early in differentiation that completely change the fate of a young NCC.
A closer look at Shah et al.’s 1994 Cell publication reveals advanced techniques that set an impressive foundation for future NCC studies. In order to understand neuregulin’s role in SC development, the paper aimed to answer the following question: When do NC-derived cells first start responding to neuregulins? Scientists used antibody staining, or immunocytochemistry, to fluorescently label NCCs with key proteins to track SC development as well as neuronal development for contrast. They stained for three proteins: 1) glial fibrillary acidic protein (GFAP) to tag immature SCs, 2) a mature Schwann cell-associated tyrosine kinase, c-Neu, and 3) peripherin to track cells developing into neurons. By analyzing NCC colonies from their early, undifferentiated state, scientists were able to study neuregulin’s instructional role in SC development.
The study found colonies of NCCs grown in neuregulin-1 to have no peripherin staining but intense GFAP staining, indicative of high levels of developing SCs and no developing neurons. This result suggests that the presence of neuregulin guides NCCs towards SC development and away from neuronal development. To confirm this result, scientists tested neuregulin-positive cell colonies for two additional Schwann cell-specific markers: P0 and O4. The presence of these protein markers in the neuregulin-treated colonies precisely identifies the cells as SCs, thus confirming neuregulin’s role in exclusively instructing SC differentiation. To confirm neuregulin’s unique role in promoting SC differentiation while suppressing neuronal differentiation, Shah et al. conducted careful colony analysis to confirm that the control and neuregulin-treated colonies had similar percentages of colony survival. This result shows that neurons were inhibited from ever forming in the first place rather than later degrading in neuregulin-positive media [2]. This experiment used rigorous colony analysis and previously validated protein markers to confirm their hypothesis of neuregulin’s two-pronged effects in directing NCC fate.
Yang et al.’s 2020 publication work builds upon Shah’s 1994 publication to examine the interplay between neuregulin and Sox10. This research is important because the study of individual protein factors is not enough to understand the complex control of a developmental process such as SC differentiation. The scientists isolated three groups of bone marrow mesenchymal stem cells (BMSCs) from mice: a control cell group with standard induction factors, a group in which neuregulin’s main receptor was blocked, and one group that never received any neuregulin. RT-PCR was used to quantify the amount of key transcriptional regulator proteins as a measure of the degree of stem cell differentiation into Schwann-like cells. The most significant results come from the ErbB2-inhibited cells treated with immunofluorescence staining, which exhibited significant decreases in multiple SC markers, large reductions in SC proliferation, and a significant decrease in Sox10 expression. These results show that ErbB2 and neuregulin are required to work together to induce stem cell differentiation into SCs. Further analysis of these results uncovered a positive feedback loop between neuregulin and Sox10, meaning the two factors’ reaction yields high amplification of the signals required to quickly create mature SCs in the developing embryo [6].
Conclusion
Current state of theory
As of this year, the entire path from NCCs to SCs is still not completely understood. It is difficult to create conditions that allow both NCC induction and the maintenance of their undifferentiated state. A second difficulty arises because new proteins are frequently added to a puzzle of cell signaling that is also not yet fully understood. There are only a few transcriptional regulators of NCCs that have been studied in detail, and little is known about the products of effector genes for the migration of NCCs [3]. As established in this review, at least four major cell signaling pathways are described to affect SC development. However, a comprehensive map of how these different pathways communicate and combine to deliver the product of mature SCs is not yet defined. Sox10 continues to be a key factor in SC differentiation, and its regulation proves to be more and more complicated with each new protein factor discovery. Nonetheless, the collective of rigorous science allows clarity to be found bit by bit, and there is great potential in the future of NCC-based therapeutics.
Figure 3: Summary of the molecular interactions between Sox10 and the four protein factors described in this review, guiding NCCs through the process of SC differentiation.
Important questions for future research
A key area of inquiry examines how this research on animal models might translate to regenerative medicine and stem cell-based therapeutics in humans. To be therapeutic for regenerative medicine, induced NCCs need to have as close to normal differentiation and population patterns as possible. This involves future research on functional comparisons between NC-derived stem cells in postnatal organisms and embryonic stem cells [5]. SCs hold a high potential for regenerative medicine due to their natural role in axonal regrowth following peripheral nerve damage [10]. The applications of this research are exciting, but there is still a long way to go in understanding the wide range of applicable protein activities.
Understanding normal patterns of SC development will help develop treatments for abnormal patterns, like SC tumors. Uncontrollable SC differentiation is a known characteristic of some cancers [1]. Recent research has identified a tumor suppressor, Nf2, that leads to Schwannomas and hyperplasia in mouse models when inactivated [3]. In addition, future manipulation of the Hippo signaling described in this article could compensate for myelin insufficiency without risking an overproduction of myelin that may lead to tumors [1]. The wide range of proteins described thus far as regulators ofSox10’s activity demonstrates the importance of continued funding for basic SC research. Finally, the modular content of this review supports the importance of further studies that focus on the interplay between cell signaling pathways to one day obtain a highly detailed, web-like recipe for SC differentiation.
References:
- Deng, Y., Wu, L. M. N., Bai, S., Zhao, C., Wang, H., Wang, J., et al. 2017. “A reciprocal regulatory loop between TAZ/YAP and G-protein Gas regulates Schwann cell proliferation and myelination.” Nat. Commun. 8, 1–15. doi: 10.1038/ncomms15161.
- Shah, N. M., Marchionni, M. A., Isaacs, I., Stroobant, P., & Anderson, D. J. 1994. “Glial Growth Factor Restricts Mammalian Neural Crest Stem Cells to a Glial Fate.” Cell, 77, 349-360.
- Méndez-Maldonado, K., Vega-López, G. A., Aybar, M. J., & Velasco, I. 2020. “Neurogenesis From Neural Crest Cells: Molecular Mechanisms in the Formation of Cranial Nerves and Ganglia.” Frontiers in Cell and Developmental Biology, 8: 1-15. doi:10.3389/fcell.2020.00635.
- Kunisada, T., Tezulka, K., Aoki, H., & Motohashi, T. 2014. “The stemness of neural crest cells and their derivatives.” Birth Defects Research Part C: Embryo Today: Reviews, 102(3), 251-262. doi:10.1002/bdrc.21079
- Perera, S. N., & Kerosuo, L. 2020. “On the road again – establishment and maintenance of stemness in the neural crest from embryo to adulthood.” Stem Cells Journals. doi:https://doi.org/10.1002/stem.3283
- Yang, X., Ji, C., Liu, X., Zheng, C., Zhang, Y., Shen, R., & Zhou, Z. 2020. “The significance of the neuregulin-1/ErbB signaling pathway and its effect on Sox10 expression in the development of terminally differentiated Schwann cells in vitro.” International Journal of Neuroscience, 1-10. doi:10.1080/00207454.2020.1806266
- Buchstaller J, Sommer L, Bodmer M, et al. 2004. “Efficient isolation and gene expression profiling of small numbers of neural crest stem cells and developing Schwann cells.” Journal of Neuroscience. 24: 2357-2365.
- Jagalur NB, Ghazvini M, Mandemakers W, et al. 2011. “Functional dissection of the Oct6 Schwann cell enhancer reveals an essential role for dimeric Sox10 binding.” Journal of Neuroscience.;31(23):8585–8594.
- Jacob, C., Lotscher, P., Engler, S., Baggiolini, A., Tavares, S. V., Brugger, V., Suter, U. 2014. “HDAC1 and HDAC2 Control the Specification of Neural Crest Cells into Peripheral Glia.” Journal of Neuroscience, 34(17), 6112-6122. doi:10.1523/jneurosci.5212-13.2014.
- Nishio, Y., Nishihira, J., Ishibashi, T., Kato, H., & Minami, A. 2002. “Role of Macrophage Migration Inhibitory Factor (MIF) in Peripheral Nerve Regeneration: Anti-MIF Antibody Induces Delay of Nerve Regeneration and the Apoptosis of Schwann Cells.” Molecular Medicine, 8(9), 509-520. doi:10.1007/bf03402160.
Genetic algorithms: An overview of how biological systems can be represented with optimization functions
By Aditi Goyal, Genetics & Genomics, Statistics ‘22
Author’s Note: As the field of computational biology grows, machine learning continues to have larger impacts in research, genomics research in particular. Genetic algorithms are an incredible example of how computer science and biology work hand in hand and can provide us with information that would otherwise take decades to obtain. I was inspired to write a review overviewing genetic algorithms and their impact on biology research after reading a news article about them. This paper is not intended to serve as a tutorial of any kind when it comes to writing a genetic algorithm. Rather, it serves to introduce this concept to someone with little to no background in computer science or bioinformatics.
Introduction
In 2008, Antoine Danchin wrote that “there is more than a crude metaphor behind the analogy between cells and computers.” [1] He also stated that the “genetic program is more than a metaphor and that cells, bacteria, in particular, are Turing machines.” [1] This is the fundamental theory that has been the basis of systems biology and has inspired the development of genetic algorithms. Genetic algorithms (GAs) provide a method to model evolution. They are based on Darwin’s theory of evolution, and computationally create the conditions of natural selection. Using genetic algorithms, one can track the progression of a certain gene or chromosome throughout multiple generations. In this paper, we discuss the components of a genetic algorithm, and how they can be modified and applied for various biological studies.
Background
GA’s are an example of a metaheuristic algorithm that is designed to find solutions to NP-hard problems [2, 3]. NP problems, aka Non-deterministic Polynomial-time problems, describe optimization problems that take a polynomial amount of time to solve via a brute force method. This is best understood through an example, the most classic one being the Traveling Salesman Problem [4]. If a salesman has to travel to five different locations, how should he pick the order of his destinations, in order to minimize the distance he travels? The solution to this problem is to calculate the total distance for each combination and pick the shortest route. At five destinations alone, there are 120 possible routes to consider. Naturally, as the number of ‘destinations’ increases, the number of possible routes will increase, as will the time it takes to calculate all options. In more complicated scenarios, such as an evolution prediction system, this problem becomes exponentially more difficult to solve, and therefore requires optimization.
GA’s are “problem independent” optimization algorithms [2, 3]. This means that the parameterization of the algorithm does not depend on any certain situation, and can be modified by the user depending on the situation. This class of optimization algorithms is often referred to as a metaheuristic algorithm. The key idea is that these types of optimization functions trade accuracy for efficiency. Essentially, they aim to approximate a solution using the least amount of time and computing power, as opposed to providing a high degree of accuracy that may take significantly more resources.
Components of a Genetic Algorithm
There are only two components essential to creating a GA: a population, and a fitness function [I*]. These two factors are sufficient to create the skeleton of a GA. Withal, most GA’s are modeled after Darwin’s theory of evolution [j*]. They use the components of fitness, inheritance, and natural variation through recombination and mutation to model how a genetic lineage will change and adapt over time [j*]. Therefore, these components must also be incorporated into the GA in order to more accurately mimic natural selection.
Population
A population is defined using the first generation, or F1. This can be a set of genes, chromosomes, or other units of interest [7]. This generation can be represented in several ways, but the most common technique is to use a bit array where different permutations of 0’s and 1’s represent different genes [7].
Selection & Fitness Functions
Now that a population has been initialized, it needs to undergo selection. During selection, the algorithm needs to select which individuals from the population will be continuing onto the next generation. This is done through the fitness function [3]. The fitness function aims to parameterize the survival of a certain individual within the population and provide a fitness score. This accounts for the fitness of each genetic trait and then computes the probability that the trait in question will continue onwards. The fitness score can be represented in different ways. A common method is using a binary system. For example, consider a chromosome being defined as a set of bits (see Figure 1). A neutral, or wild-type allele can be represented with a zero. A beneficial allele or one that confers some sort of advantage over the wild-type is represented using a 1. The fitness function would then be defined to calculate the fitness of each chromosome. In this example, the fitness is equivalent to the sum of the binary scores.
Chromosomes with a higher fitness score represent chromosomes that have more beneficial traits as compared to chromosomes with lower fitness scores. Therefore, chromosomes that maximize the fitness score will be preferred.
Inheritance & Genetic Variation
The fittest individuals are then propagated onwards to the “breeding” phase, while only a small proportion of the fewer fit individuals are carried forward. This is the step that mimics “natural selection”, as we are selecting for the more fit individuals, and only a small proportion of the fewer fit individuals are surviving due to chance.
Now that the survivors have been identified, we can use GA operators to create the next generation. GA operators are how genetic variation is modeled [7]. As such, the two most common operators in any GA are mutation rates and recombination patterns. The F2 generation is created by pairing two individuals from F1 at random and using our operators to create a unique F2.
Mutations are commonly represented using bit changes [3]. Because our original population was defined in binary, our mutation probability function represents the probability of a bit switch, i.e. the probability that a 0 would switch to a 1, or vice versa. These probabilities are usually quite low and have a minor impact on the genetic variation.
Recombination, or crossovers, is where the majority of new genetic variations arise. These are modeled by choosing a point of recombination, and essentially swapping bit strings at that point. A simple GA uses a single point crossover, where only one crossover occurs per chromosome. However, a GA can easily be adapted to have multiple crossover points [8, 9].
On average, via the mutation and crossover operators, the fitness level of F2 should be higher than F1. By carrying some of the fewer fit individuals, we allow for a larger gene pool and therefore allow for more possibilities for genetic combinations, but the gene pool should be predominated by favorable genes [3].
Termination
This three-step pattern of selection, variation, and propagation is repeated until a certain threshold is reached. This threshold can be a variety of factors, ranging anywhere from a preset number of generations to a certain average fitness level. Typically, termination occurs when population convergence occurs, meaning that the offspring generation is not significantly better than the generation before it [10].
Modifications to GA’s
As one can see, this is a rather simplistic approach to evolution. There are several biological factors that remain unaddressed in a three-step process. Consequently, there are many ways to expand a GA to more closely resemble the complexity of natural evolution. The following section shall briefly overview a few of the different techniques used in tandem with a GA to add further resolution to this prediction process.
Speciation
A GA can be combined with a speciation heuristic that discourages crossover pairs between two individuals that are very similar, allowing for more diverse offspring generations [11, 12]. Without this speciation parameter, early convergence is a likely possibility [12]. Early convergence describes the event that the ideal individual, i.e. the individual with the optimized fitness score, is reached in too few generations.
Elitism
Elitism is a commonly used approach to ensure that the fitness level will never decrease from one generation to the next [13]. Elitism describes the decision to carry on the highest-rated individuals from one generation to the next with no change [13, 14]. Elitism also ensures that genetic information is not lost. Since each offspring must be ‘equal or better’ than the generation before it, it is guaranteed that the parental genotypes will carry through generations, changing at a much slower rate than a pure GA would model [15].
Adaptive Genetic Algorithms
Adaptive Genetic Algorithms (AGA’s) are a burgeoning subfield of GA development. An AGA will continuously modify the mutation and crossover operators in order to maintain population diversity, while also keeping the convergence rate consistent [16]. This is computationally expensive but often produces more realistic results, especially when calculating the time it would take to reach the optimal fitness. The Mahmoodabadi et al team compared AGA’s to 3 other optimization functions and found that “AGA offers the highest accuracy and the best performance on most unimodal and multimodal test functions” [17].
Interactive Genetic Algorithms
As previously stated, the fitness function is critical to creating a GA. However, there arise several instances where a fitness function cannot be accurately defined. This is particularly true for species that have elaborate mating rituals, as that is a form of selection that would be computationally expensive to recreate. In these situations, one can use an interactive genetic algorithm (IGA). IGA’s operate in a similar fashion to GA’s, but they require user input at the fitness calculation point.
While this method does provide some way of modeling a population without having a predefined fitness function, it has glaring drawbacks. Primarily, this process is not feasible for large populations, as it puts the burden of calculating the fitness on the user, and it also leaves room for subjective bias from the user. However, this subjective component been viewed as an advantage in several fields, particularly the fashion industry [18]. Designers have been investigating IGA’s as a method to generate new styles, as the algorithm depends on user validation of what is considered to be a good design versus a bad one [18].
Applications
Genetic algorithms have a far-reaching effect on computational efforts in every field, especially in biology. As the name suggests, genetic algorithms have a huge impact on evolutionary biology, as they can assist with phylogeny construction for unrooted trees [19]. Oftentimes, evolutionary data sets are incomplete. This can result in billions of potential unrooted phylogenetic trees. As the Hill et al team describes, “for only 13 taxa, there are more than 13 billion possible unrooted phylogenetic trees,” [19].
Testing each of these combinations and determining the best fit is yet another example of an optimization problem– one which a GA can easily crack. Hill et al applied a GA to a set of amino acid sequences and built a phylogenetic tree comparing protein similarities [19]. They found that a program called Phanto, “infers the phylogeny of 92 taxa with 533 amino acids, including gaps in a little over half an hour using a regular desktop PC” [19].
Similarly, the Wong et al team tackled the infamous protein folding prediction problem using GA’s [20]. They used the HP Lattice model to simplify a protein structure and used the iterative nature of a GA to find a configuration that minimized the energy required to fold a protein into that shape. The HP Lattice model stands for Hydrophobic Polar Lattice and seeks to model the hydrophobicity interactions that occur between different amino acid residues in the secondary structure of a protein [20]. They found that a GA performed better than some of the newer protein folding predictive programs available today [20].
GA’s are an incredible tool for cancer research as well. The Mitra et al team used a GA to study bladder cancer [21]. They conducted quantitative PCR on tissue samples from 65 patients and identified 70 genes of interest. Of these 70 genes, three genes in particular, were identified in a novel pathway. They discovered that ICAM1 was up-regulated relative to MAP2K6, while MAP2K6 was up-regulated relative to KDR. This pathway was considered to be novel because individually, all three genes displayed no signs of significant changes in regulation. By applying a GA, the Mitra team was able to identify this pattern between all three genes. Uncoincidentally, “ICAM1 and MAP2K6 are both in the ICAM1 pathway, which has been reported as being associated with cancer progression, while KDR has been reported as being associated with the vascularization supporting tumors” [21, 22, 23].
Another groundbreaking discovery was made by applying GA’s to p53 research. P53 is an essential tumor suppressor [24]. Most cancerous tumors can be attributed, in part, to a mutation in the p53 gene, making it an excellent candidate for oncology research. The Millet et al team investigated a possible p53 gene signature for breast cancer, hoping to find an accurate prediction system for the severity of breast cancer [25]. They analyzed 251 transcriptomes from patient data and found a 32 gene signature that could serve as a predictor for breast cancer severity [23, 25]. They also found that “the p53 signature could significantly distinguish patients having more or less benefit from specific systemic adjuvant therapies and locoregional radiotherapy,” [25].
GA’s have also had a huge impact on immunology, vaccine development in particular. Licheng Jiao and Lei Wang developed a new type of GA called the Immunity Genetic Algorithm [26]. This system mimics a typical GA but adds a two-step ‘immunological’ parameter (Figure 3). Much like a GA, the fitness function is applied to a population, which then triggers mutation and crossover. However, after these steps, the program mimics ‘vaccination’ and ‘immune selection. These two steps are referred to as the “Immune Operator” [26]. They are designed to raise a genetic advantage in individuals who respond well to the vaccine and confer a disadvantage to those with a ‘weaker’ immune response. In essence, the vaccination step acts as a secondary mutation, as it is acting as an external change factor in each individual’s fitness. Similarly, the ‘immune selection’ step acts as a secondary fitness function, as it measures the immune response post-vaccine. If evolution is continuing as it should, each generation should have an improved immune response to the vaccine until convergence is reached.
Conclusion
GA’s have a broad reach in all fields of research, from fashion to immunology. Their success is due to three critical components underlying their programming: they are simple to write, easy to customize, and efficient to run. This flexibility and independence are what will allow programs like GA’s to become commonplace in research, across all disciplines. In particular, as biology research continues to merge with computer science and advanced modeling techniques, applications like GA’s have the potential to solve problems and raise questions about our world that we may have never imagined before.
References:
- Danchin, Antoine. “Bacteria as computers making computers.” FEMS microbiology reviews vol. 33,1 (2009): 3-26. doi:10.1111/j.1574-6976.2008.00137.x
- Said, Gamal Abd El-Nasser A., Abeer M. Mahmoud, and El-Sayed M. El-Horbaty. “A comparative study of meta-heuristic algorithms for solving quadratic assignment problem.” arXiv preprint arXiv:1407.4863 (2014).
- Marek Obitko, “III. Search Space.” Search Space, courses.cs.washington.edu/courses/cse473/06sp/GeneticAlgDemo/searchs.html.
- Hoffman K.L., Padberg M. (2001) Traveling salesman problem. In: Gass S.I., Harris C.M. (eds) Encyclopedia of Operations Research and Management Science. Springer, New York, NY. https://doi.org/10.1007/1-4020-0611-X_1068
- Whitley, D. A genetic algorithm tutorial. Stat Comput 4, 65–85 (1994). https://doi.org/10.1007/BF00175354
- McCall, John. “Genetic algorithms for modelling and optimisation.” Journal of computational and Applied Mathematics 184.1 (2005): 205-222.
- Carr, Jenna. An Introduction to Genetic Algorithms. Whitman University, 2014, www.whitman.edu/Documents/Academics/Mathematics/2014/carrjk.pdf.
- Hassanat, Ahmad et al. “Choosing Mutation and Crossover Ratios for Genetic Algorithms—A Review with a New Dynamic Approach.” Information 10.12 (2019): 390. Crossref. Web.
- Gupta, Isha, & Anshu Parashar. “Study of Crossover operators in Genetic Algorithm for Travelling Salesman Problem.” International Journal of Advanced Research in Computer Science [Online], 2.4 (2011): 194-198. Web. 17 May. 2021
- Alkafaween, Esra’a. (2015). Novel Methods for Enhancing the Performance of Genetic Algorithms. 10.13140/RG.2.2.21478.04163.
- Duda, J.. “Speciation, clustering and other genetic algorithm improvements for structural topology optimization.” (1996).
- Duda, J. W., and Jakiela, M. J. (March 1, 1997). “Generation and Classification of Structural Topologies With Genetic Algorithm Speciation.” ASME. J. Mech. Des. March 1997; 119(1): 127–131.
- J. A. Vasconcelos, J. A. Ramirez, R. H. C. Takahashi and R. R. Saldanha, “Improvements in genetic algorithms,” in IEEE Transactions on Magnetics, vol. 37, no. 5, pp. 3414-3417, Sept. 2001, doi: 10.1109/20.952626.
- Ishibuchi H., Tsukamoto N., Nojima Y. (2008) Examining the Effect of Elitism in Cellular Genetic Algorithms Using Two Neighborhood Structures. In: Rudolph G., Jansen T., Beume N., Lucas S., Poloni C. (eds) Parallel Problem Solving from Nature – PPSN X. PPSN 2008. Lecture Notes in Computer Science, vol 5199. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-87700-4_46
- Thierens, Dirk. Selection schemes, elitist recombination, and selection intensity. Vol. 1998. Utrecht University: Information and Computing Sciences, 1998.
- C. Lin, “An Adaptive Genetic Algorithm Based on Population Diversity Strategy,” 2009 Third International Conference on Genetic and Evolutionary Computing, 2009, pp. 93-96, doi: 10.1109/WGEC.2009.67.
- Mahmoodabadi, M. J., and A. R. Nemati. “A novel adaptive genetic algorithm for global optimization of mathematical test functions and real-world problems.” Engineering Science and Technology, an International Journal 19.4 (2016): 2002-2021.
- Cho, Sung-Bae. “Towards creative evolutionary systems with interactive genetic algorithm.” Applied Intelligence 16.2 (2002): 129-138.
- Hill, Tobias, et al. “Genetic algorithm for large-scale maximum parsimony phylogenetic analysis of proteins.” Biochimica et Biophysica Acta (BBA)-General Subjects 1725.1 (2005): 19-29.
- van Batenburg FH, Gultyaev AP, Pleij CW. An APL-programmed genetic algorithm for the prediction of RNA secondary structure. J Theor Biol. 1995 Jun 7;174(3):269-80. doi: 10.1006/jtbi.1995.0098. PMID: 7545258.
- Mitra, A.P., Almal, A.A., George, B. et al. The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer. BMC Cancer 6, 159 (2006). https://doi.org/10.1186/1471-2407-6-159
- Hubbard AK, Rothlein R. Intercellular adhesion molecule-1 (ICAM-1) expression and cell signaling cascades. Free Radic Biol Med. 2000;28:1379–1386.
- Worzel, William P et al. “Applications of genetic programming in cancer research.” The international journal of biochemistry & cell biology vol. 41,2 (2009): 405-13. doi:10.1016/j.biocel.2008.09.025
- National Center for Biotechnology Information (US). Genes and Disease [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 1998-. The p53 tumor suppressor protein. Available from: https://www.ncbi.nlm.nih.gov/books/NBK22268/
- Miller LD, Smeds J, Joshy G, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proceedings of the National Academy of Sciences. 2005 Sep 20;102(38):13550–5.
- Jiao, Licheng, and Lei Wang. “A novel genetic algorithm based on immunity.” IEEE Transactions on Systems, Man, and Cybernetics-part A: systems and humans 30.5 (2000): 552-561.
A Neuroimmunological Approach to Understanding SARS-CoV-2
By Parmida Pajouhesh, Neurobiology, Physiology & Behavior ‘23
Author’s Note: The Coronavirus Disease has undoubtedly affected us in many sectors of our lives. There has been a lot of discussion surrounding the respiratory symptoms induced by the disease but less focus on how contracting the disease can result in long-term suffering. As someone who is fascinated by the brain, I wanted to investigate how COVID-19 survivors have been neurologically impacted post-recovery and what insight it can provide on more severe neurological disorders.
The Coronavirus Disease (COVID-19) has drastically changed our lives over the past fifteen months. The viral disease produces mild to severe symptoms, including fever, chills, and nausea. There are individual differences in the length of recovery, typically ranging from 1-2 weeks after contraction [1]. Once recovered, those infected are assumed to be healthy and “back to normal,” but data shows that this is not the case for some COVID-19 survivors. COVID-19 has resulted in more severe long-term effects for patients, greatly affecting their ability to perform daily tasks. Taking a deeper look into the neuroimmunological side effects of COVID-19 can help explain the long-term symptoms experienced by survivors.
Developing our knowledge of long-term neurological effects on COVID-19 survivors is crucial in understanding the risk of cognitive impairments, including dementia and Alzheimer’s disease [2].
A team led by Dr. Alessandro Padovani at the University of Brescia recruited COVID-19 survivors with no previous neurological disease or cognitive impairment for check-ins six months after infection [3]. The exam assessed motor and sensory cranial nerves and global cognitive function. The results showed that the most prominent symptoms were fatigue, memory complaints, and sleep disorder. Notably, these symptoms were reported much more frequently in patients who were older in age and hospitalized for a longer period of time [3].
Other symptoms reported include “brain fog,” a loss of taste or smell, and brain inflammation [2]. Researchers hypothesize that the virus does not necessarily need to make its way inside neurons to result in “brain fog” but instead claim that it is an attack on the sensory neurons, the nerves that extend from the spinal cord throughout the body to gather information from the external environment. When the virus hijacks nociceptors, neurons that are specifically responsible for sensing pain, symptoms like brain fog can follow [4].
Theodore Price, a neuroscientist at the University of Texas at Dallas, investigated the relationship between nociceptors and angiotensin-converting enzyme 2 (ACE2), a protein embedded in cell membranes that allows for viral entry when the spike protein of SARS-CoV-2 binds to it [4, 5]. The nociceptors live in clusters around the spinal cord, which are called dorsal root ganglia (DRG). Price determined that a set of DRG neurons did contain ACE2, enabling the virus to enter the cells. The DRG neurons that contained ACE2 had messenger RNA for the sensory protein MRGPRD, which marks neurons with axons concentrated at the skin, inner organs and lungs. If sensory neurons are infected with the virus, it can result in long-term consequences. It might not be the case that the virus is directly entering the brain and infecting the sensory neurons. Alternatively, it is the immune response triggering an effect on the brain, which leads to the breakdown of the blood-brain barrier surrounding the brain [6]. While this area of research is still under investigation, studies have shown that the breakdown of the blood-brain barrier and lack of oxygen to the brain are hallmarks of Alzheimer’s disease and dementia. Scientists are tracking global function to further understand the impact of COVID-19 treatments and vaccines on these neurological disorders.
Understanding whether the cause of neurological symptoms is viral brain infection or immune activity is important to clinicians who provide intensive care and prescribe treatments [2, 6]. With future studies, researchers plan to further examine the causes of these symptoms. This knowledge will hopefully provide COVID-19 survivors with adequate support to combat these difficulties and reduce their risk of developing a more severe neurological disorder in the future.
References :
- Sissons, Beth. 2021. “What to Know about Long COVID.” Medical News Today. www.medicalnewstoday.com/articles/long-covid#diagnosis
- Rocheleau, Jackie. 2021. “Researchers Are Tracking Covid-19’s Long-Term Effects On Brain Health.” Forbes. www.forbes.com/sites/jackierocheleau/2021/01/29/researchers-are-tracking-covid-19s-long-term-effects-on-brain-health/?sh=59a0bb284303
- George, Judy. 2021. “Long-Term Neurologic Symptoms Emerge in COVID-19.” MedPage Today. www.medpagetoday.com/infectiousdisease/covid19/90587
- Sutherland, Stephani. 2020. “What We Know So Far about How COVID Affects the Nervous System.” Scientific American. www.scientificamerican.com/article/what-we-know-so-far-about-how-covid-affects-the-nervous-system
- Erausquin, Gabriel A et al. 2021. “The Chronic Neuropsychiatric Sequelae of COVID‐19: The Need for a Prospective Study of Viral Impact on Brain Functioning.” Alzheimer’s & Dementia. Crossref, doi:10.1002/alz.12255
- Marshall, Michael. 2020. “How COVID-19 Can Damage the Brain.” Nature. www.nature.com/articles/d41586-020-02599-5?error=cookies_not_supported&code=5b856480-d7e8-4a22-9353-9000e12a8962
Psychedelics Herald New Era of Mental Health
By Macarena Cortina, Psychology ‘21
Author’s Note: As a psychology major who used to be a plant biology major, I’m very interested in the arenas where these two fields interact. Such is the case with psychoactive plants and fungi that produce significant alterations in brain chemistry and other aspects of the human psyche. That is why I chose to write about psychedelics and their rebirth in both research and culture. In the past few months, I have seen increasing media coverage of new scientific findings about these substances, as well as legal advancements in their decriminalization, making this a relevant topic in the worlds of psychology and ethnobotany. The history of psychedelics is a long and complicated one, but here I attempt to cover the basics in hopes of demystifying these new powerful therapeutic treatments and informing readers about the latest horizon in mental health.
After decades in the dark, psychedelic drugs are finally resurfacing in the world of science and medicine as potential new tools for mental health treatment. Psychedelics, otherwise known as hallucinogens, are a class of psychoactive substances that have the power to alter mood, perception, and cognitive functions in the human brain. They include drugs such as LSD, magic mushrooms, ayahuasca, MDMA, and peyote [1]. The US has a long and complex history with these drugs, and the resulting criminalization and stigma associated with them have kept psychedelics in the shadows for many years. However, a major shift in society’s opinions of psychedelics is taking place, and a reawakening is happening in the scientific community. Researchers from various disciplines are becoming increasingly interested in unlocking the therapeutic powers of these compounds, especially for those who are diagnosed with mental disorders and are resistant to the treatments that are currently available for them. Whether or not the world is ready for it, the psychedelic renaissance has begun.
Psychedelics have been used by Indigenous communities around the world as part of their cultural, spiritual, and healing traditions for thousands of years. In the Western world, psychedelics were rediscovered in the 1940s by Swiss chemist Albert Hofmann, who accidentally absorbed LSD through his skin while conducting tests for a potential medicine [2]. What followed was an “uninterrupted stream of fantastic pictures, extraordinary shapes, with intense, kaleidoscopic play of colors” [7]. Once LSD was disseminated throughout the world, psychologists began to experiment with it as a psychotomimetic, or a drug that mimics psychosis, in hopes of gaining a better understanding of schizophrenia and similar mental disorders [2, 3]. In the 1950s, as a result of the US government’s fear that communist nations were using mind control to brainwash US prisoners of war, the CIA carried out the top-secret project MK-Ultra, drugging even unwitting subjects with psychedelics in an attempt to learn about potential mind control techniques [4]. Recreational use of psychoactive substances proliferated in the counterculture movement of the 1960s, eventually leading to their criminalization and status as Schedule 1 drugs [5]. This classified them as substances with no medical value and a high potential for abuse—two descriptors we know are not factual [6].
Now, people seem to be reevaluating their outlook on these formerly demonized drugs and are instead looking for ways to harness psychedelics’ medicinal properties for mental and physical improvement. Momentum is building quickly. Clinical trials are beginning to show real potential in the use of psychedelics for the treatment of depression, anxiety, post-traumatic stress disorder (PTSD), addiction, eating disorders, and emotional suffering caused by diagnosis of a terminal illness. The US Food and Drug Administration (FDA) has already approved the use of ketamine for therapeutic purposes with MDMA and psilocybin set to follow [7]. Psilocybin has also been decriminalized in cities across the US and was completely legalized for medical use in the entire state of Oregon in November 2020. Entrepreneurs and investors are flocking to startups such as MAPS Public Benefit Corporation and Compass Pathways, which are currently developing psychedelic drugs for therapeutic application. Research centers have been cropping up across the country as well, even at prestigious institutions like John Hopkins School of Medicine and Massachusetts General Hospital.
So how do psychedelics work? In truth, scientists still don’t know exactly what happens to neural circuitry under the influence of these mind-altering drugs. While more research is required to fully understand how psychedelics affect the brain, there are some findings that help clarify this mystery. For example, the major group of psychedelics—called the “classic psychedelics”—closely resembles the neurotransmitter serotonin in terms of molecular structure [8]. This group includes psilocin, one of the important components of magic mushrooms; 5-MeO-DMT, which is present in a variety of plant species and at least one toad species; and LSD, also known as acid [8]. What they all have in common is a tryptamine structure, characterized by the presence of one six-atom ring linked to a five-atom ring [8]. This similarity lends itself to a strong affinity between these psychedelics and serotonin receptors in the cerebral cortex, particularly the receptor 5-HT2A [8]. The implication of this is that psychedelics can have a significant and widespread influence on brain chemistry, given that serotonin is one of the main neurotransmitters in the brain and plays a major role in mood regulation [9].
What follows is a poorly understood cascade of effects that causes disorganized activity across the brain [10]. At the same time, it seems that the brain’s default-mode network gets inhibited. British researcher Robin Carhart-Harris recently discovered this by dosing study participants with either psilocybin or LSD and examining their neural activity with the help of fMRI (functional magnetic resonance imaging). Rather than seeing what most people expected—an excitation of brain networks—Dr. Carhart-Harris found a decrease of neuronal firing in the brain, specifically in the default-mode network. According to Michael Pollan, author of the best-selling book on psychedelics How to Change Your Mind, this network is a “tightly linked set of structures connecting the prefrontal cortex to the posterior cingulate cortex to deeper, older centers of emotion and memory.” Its function appears to involve self-reflection, theory of mind, autobiographical memory, and other components that aid us in creating our identity. In other words, the ego—the conscious sense of self and thus the source of any self-destructive thoughts that may arise—seems to be localized in the default-mode network. This network is at the top of the hierarchy of brain function, meaning it regulates all other mental activity [10].
Therefore, when psychedelics enter the system and quiet the default-mode network, suddenly new and different neural pathways are free to connect, leading to a temporary rewiring of the brain [10]. In many cases, this disruption of normal brain functioning has reportedly resulted in mystical, spiritual, and highly meaningful experiences. Psychedelics facilitate neuroplasticity, thereby helping people break negative thinking patterns and showing them—even temporarily—that it’s possible to feel another way or view something from a different (and more positive) perspective.
This kind of experience can be immensely helpful to someone who is struggling with a mental health disorder and needs a brain reset. While other techniques, such as meditation and general mindfulness, can help cultivate a similar feeling, they require much more time and effort, something that is not always feasible—and never easy—for those who are severely struggling with their mental health [10]. Psychedelics can help jump-start the process of healing, and their effects can be made even more powerful and long-lasting when coupled with psychotherapy [11]. Talking with a psychiatrist or psychologist after the drug treatment can help integrate and solidify a client’s newly acquired thinking patterns [11].
In a study published in The New England Journal of Medicine in April 2021, researchers found that psilocybin works at least as well as leading antidepressant escitalopram [12]. In this double-blind, randomized, controlled trial, fifty-nine participants with moderate-to-severe depression took either psilocybin or escitalopram, along with a placebo pill in both cases. After six weeks, participants in both groups exhibited lower scores on the 16-item Quick Inventory of Depressive Symptomatology–Self-Report (QIDS-SR-16), indicating an improvement in their condition. The difference in scores between the two groups was not statistically significant, meaning that a longer study with a larger sample size is still required to show if there is an advantage to treating depression with psilocybin over conventional drugs [12]. However, one notable difference was that psilocybin seems to take effect faster than escitalopram [13]. As an SSRI (selective serotonin reuptake inhibitor), escitalopram takes a couple months to work, something that’s not helpful for those with severe depression. Psilocybin, then, is suggested to provide more immediate relief to people battling depression [13].
In June 2020, a team of researchers at John Hopkins published a meta-analysis of nine clinical trials concerning psychedelic-assisted therapy for mental health conditions such as PTSD, end-of-life distress, depression, and social anxiety in adults with autism [14]. These were all the “randomized, placebo-controlled trials on psychedelic-assisted therapy published [in English] after 1993.” The psychedelics in question included LSD, psilocybin, ayahuasca, and MDMA. Following their statistical meta-analysis of these trials, they found that the “overall between-group effect size at the primary endpoint for psychedelic-assisted therapy compared to placebo was very large (Hedges g = 1.21). This effect size reflects an 80% probability that a randomly selected patient undergoing psychedelic-assisted therapy will have a better outcome than a randomly selected patient receiving a placebo” [14].
There were only minimal adverse effects reported from this kind of therapy and no documentation of serious adverse effects [14]. When compared to effect sizes of pharmacological agents and psychotherapy interventions, the effects of psychedelic-assisted therapy were larger, especially considering the fact that participants received the psychedelic substance one to three times prior to the primary endpoint, as opposed to daily or close-to-daily interventions with psychotherapy or conventional medications. Overall, results suggest that psychedelic-assisted therapy is effective—with minimal adverse effects—and presents a “promising new direction in mental health treatment” [14].
At UC Davis, researchers in the Olson Lab recently engineered a drug modeled after the psychedelic ibogaine [15]. This variant, called tabernanthalog (TBG), was designed to induce the therapeutic effects of ibogaine minus the toxicity or risk of cardiac arrhythmias that make consuming ibogaine less safe. TBG is a non-hallucinogenic, water-soluble compound that can be produced in merely one step. In an experiment performed with rodents, “tabernanthalog was found to promote structural neural plasticity, reduce alcohol- and heroin-seeking behavior, and produce antidepressant-like effects.” These effects should be long lasting given that TBG has the ability to modify the neural circuitry related to addiction, making it a much better alternative to existing anti-addiction medications. And since the brain circuits involved in addiction overlap with those of conditions like depression, anxiety, and post-traumatic stress disorder, TBG could help treat various mental health issues [15].
As the psychedelic industry begins to emerge, members of the psychedelic community are voicing their concerns about the risks that come with rapid commercialization [7]. Biotech companies, researchers, and therapists should be careful about marketing psychedelics as a casual, quick fix to people’s problems. Psychedelics can occasion intense and profound experiences and should be consumed with the right mindset, setting, and guidance. There are still many unknowns about psychedelic use, especially its long-term effects. Not all individuals should try treatment with psychedelics, especially those with a personal or family history of psychosis. It will also be important to move forward in a way that is respectful to Indigenous traditions and accessible to all people—particularly people of color—without letting profit become the main priority. Some advocates worry that commercialization and adoption into a pharmaceutical model might strip psychedelics of their most powerful transformational benefits and that they will wind up being used merely for symptom resolution [7]. As long as psychedelics’ reintroduction to mainstream medicine is handled mindfully, the world may soon have a new avenue for effective mental health therapy that honors its Indigenous heritage and is accessible to all.
References:
- Alcohol & Drug Foundation. Psychedelics. October 7, 2020. Available from https://adf.org.au/drug-facts/psychedelics/.
- Williams L. 1999. Human Psychedelic Research: A Historical And Sociological Analysis. Cambridge University: Multidisciplinary Association for Psychedelic Studies.
- Sessa B. 2006. From Sacred Plants to Psychotherapy:The History and Re-Emergence of Psychedelics in Medicine. Royal College of Psychiatrists.
- History. MK-Ultra. June 16, 2017. Available from https://www.history.com/topics/us-government/history-of-mk-ultra.
- Beres D. Psychedelic Spotlight. Why Are Psychedelics Illegal? October 13, 2020. Available from https://psychedelicspotlight.com/why-are-psychedelics-illegal/.
- United States Drug Enforcement Administration. Drug Scheduling. Available from https://www.dea.gov/drug-information/drug-scheduling.
- Gregoire C. NEO.LIFE. Inside the Movement to Decolonize Psychedelic Pharma. October 29, 2020. Available from https://neo.life/2020/10/inside-the-movement-to-decolonize-psychedelic-pharma/.
- Pollan M. How to Change Your Mind: What the New Science of Psychedelics Teaches Us About Consciousness, Dying, Addiction, Depression, and Transcendence. New York: Penguin Press; 2018.
- Bancos I. Hormone Health Network. What is Serotonin? December 2018. Available from https://www.hormone.org/your-health-and-hormones/glands-and-hormones-a-to-z/hormones/serotonin#:~:text=Serotonin%20is%20the%20key%20hormone, sleeping%2C%20eating%2C%20and%20digestion.
- Pollan M, Harris S, Silva J, Goertzel B. December 11, 2020. Psychedelics: The scientific renaissance of mind-altering drugs. YouTube: Big Think. 1 online video: 20 min, sound, color.
- Singer M. 2021. Trip Adviser.Vogue. March issue: 198-199, 222-224.
- Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, Martell J, Blemings A, Erritzoe D, Nutt DJ. 2021. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med [Internet]. 384:1402-1411. doi: 10.1056/NEJMoa2032994.
- Lee YJ. Business Insider Australia. A landmark study shows the main compound in magic mushrooms could rival a leading depression drug. April 14, 2021. Available from https://www.businessinsider.com.au/psilocybin-magic-mushroom-for-depression-takeaways-from-icl-report-nejm-2021-4.
- Luoma JB, Chwyl C, Bathje GJ, Davis AK, Lacelotta R. 2020. A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy. Journal of Psychoactive Drugs [Internet]. 52(4):289-299. doi: 10.1080/02791072.2020.1769878.
- Cameron LP, Tombari RJ, Olson DE, et al. 2020. A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature [Internet]. 589:474–479. https://doi.org/10.1038/s41586-020-3008-z.